<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: rgbpQ1.xfr; Date: 2021%2D08%2D13T17:46:30Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:RGBP="http://regenbiopharma.com/20201231">
    <link:schemaRef xlink:href="rgbp-20201231.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2021-05-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesAAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RGBP:SeriesAAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_SeriesAAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RGBP:SeriesAAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RGBP:SeriesMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_SeriesMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RGBP:SeriesMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-10-24to2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-10-24</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_DavidKoosMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:DavidKoosMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_BSTPartnersMember381225750">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_March82016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:March82016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_April62016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:April62016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_September82016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:September82016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_September202016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:September202016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_October312016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:October312016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_October3120162Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:October3120162Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_October3120163Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:October3120163Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_December222016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:December222016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_March12017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:March12017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_March92017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:March92017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_March132017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:March132017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_March312017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:March312017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_April192017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:April192017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_April1920172Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:April1920172Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_May52017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:May52017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_May102017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:May102017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_May192017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:May192017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_June262017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:June262017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_July242017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:July242017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Sept72017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Sept72017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Aug292017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Aug292017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Sept222017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Sept222017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Sept2220172Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Sept2220172Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Sept252017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Sept252017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Oct0317Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Oct0317Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Oct0417Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Oct0417Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Oct1617Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Oct1617Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Nov0117Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Nov0117Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Nov0120172Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Nov0120172Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Dec1517Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Dec1517Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Dec2017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Dec2017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Dec20172Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Dec20172Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Dec0617Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Dec0617Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Jan2418Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Jan2418Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Feb2818Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Feb2818Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_Feb2618Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Feb2618Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_May182018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:May182018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_July112018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:July112018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_August142018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:August142018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_September302018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:September302018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_October32018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:October32018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_October102018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:October102018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_January222019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:January222019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_July192019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:July192019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_July1920192Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:July1920192Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_July1920193Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:July1920193Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_March82016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:March82016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_April62016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:April62016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_September82016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:September82016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_September202016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:September202016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_October312016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:October312016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_October3120162Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:October3120162Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_October3120163Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:October3120163Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_December222016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RGBP:December222016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_March12017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:March12017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_March92017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:March92017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_March132017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:March132017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_March312017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:March312017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_April192017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:April192017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_April1920172Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:April1920172Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_May52017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:May52017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_May102017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:May102017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_May192017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:May192017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_June262017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:June262017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_July242017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:July242017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Aug292017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Aug292017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Sept222017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Sept222017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Sept2220172Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Sept2220172Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Sept252017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Sept252017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Oct0317Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Oct0317Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Oct0417Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Oct0417Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Oct1617Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Oct1617Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Nov0117Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Nov0117Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Nov0120172Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Nov0120172Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Dec1517Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Dec1517Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Dec2017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Dec2017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Dec20172Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Dec20172Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Dec0617Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Dec0617Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Jan2418Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Jan2418Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Feb2818Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:Feb2818Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_May182018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:May182018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_July112018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:July112018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_September302018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:September302018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_October32018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:October32018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_October102018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:October102018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_January222019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:January222019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_February152019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:February152019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_July192019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:July192019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_July1920192Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:July1920192Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_July1920193Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">RGBP:July1920193Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_SeriesAAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RGBP:SeriesAAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_SeriesMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RGBP:SeriesMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_us-gaap_SeriesAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-10-28_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-01to2020-11-06_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-01</xbrli:startDate>
        <xbrli:endDate>2020-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-02to2020-12-11_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-02</xbrli:startDate>
        <xbrli:endDate>2020-12-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-02to2020-12-16_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-02</xbrli:startDate>
        <xbrli:endDate>2020-12-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-03to2020-12-16_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-03</xbrli:startDate>
        <xbrli:endDate>2020-12-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-02to2020-12-17_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-02</xbrli:startDate>
        <xbrli:endDate>2020-12-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-01to2020-12-23_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-01to2020-12-31_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-01to2021-01-28_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-01to2021-02-23_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-01</xbrli:startDate>
        <xbrli:endDate>2021-02-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-01to2021-02-24_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-01</xbrli:startDate>
        <xbrli:endDate>2021-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-01to2021-03-02_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-01to2021-03-18_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-01to2021-03-31_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-01to2021-04-12_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-01to2021-04-13_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-02to2021-04-13_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-02</xbrli:startDate>
        <xbrli:endDate>2021-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-01to2021-04-15_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-02to2021-04-15_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-02</xbrli:startDate>
        <xbrli:endDate>2021-04-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-01to2021-04-16_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-02to2021-04-16_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-02</xbrli:startDate>
        <xbrli:endDate>2021-04-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-01to2021-04-21_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-01to2021-04-28_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-01to2021-05-03_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-05-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-01to2021-05-05_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-05-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-01to2020-12-17_us-gaap_ConvertibleDebtMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-01to2021-03-26_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_custom_SeriesNCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RGBP:SeriesNCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-26_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_custom_SeriesNCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RGBP:SeriesNCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RGBP:SeriesMMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:ZanderTherapeuticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:ZanderTherapeuticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:ZanderTherapeuticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RGBP:SeriesMMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:ZanderTherapeuticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-05-30to2018-06-11_custom_ZanderTherapeuticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:ZanderTherapeuticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-05-30</xbrli:startDate>
        <xbrli:endDate>2018-06-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-01to2018-11-29_custom_SeriesMMember_custom_ZanderTherapeuticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RGBP:SeriesMMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:ZanderTherapeuticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-01</xbrli:startDate>
        <xbrli:endDate>2018-11-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_ZanderTherapeuticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:ZanderTherapeuticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_DavidKoosMember94604294">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:DavidKoosMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2020-09-30_custom_DavidKoosMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:DavidKoosMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-02_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-10-02_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-10-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-04_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-10-04_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-10-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-24_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-10-24_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-10-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-25_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-10-25_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-10-31_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-06_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-01to2019-11-06_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-08_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-01to2019-11-08_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-15_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-01to2019-11-15_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-26_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-01to2019-11-26_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-02_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-01to2019-12-02_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-17_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-01to2019-12-17_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-02_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-01-02_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-10_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-01-10_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-16_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-01-16_custom_BSTPartnersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RGBP:BSTPartnersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:SeriesAPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:SeriesAPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_SeriesAAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:SeriesAAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SeriesAAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:SeriesAAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_custom_SeriesMPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:SeriesMPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_SeriesMPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:SeriesMPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SeriesMPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:SeriesMPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_custom_ContributedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:ContributedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_ContributedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:ContributedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ContributedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:ContributedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:SeriesAPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:SeriesAPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:SeriesAPreferredStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_SeriesAAPreferredStockMember68709765">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:SeriesAAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesAAPreferredStockMember68493578">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:SeriesAAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_SeriesMPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:SeriesMPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesMPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:SeriesMPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_ContributedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:ContributedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_ContributedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:ContributedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ContributedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001589150</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">RGBP:ContributedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-05-14" unitRef="Shares" decimals="INF">3746423788</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-09-30" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2021-03-26_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_custom_SeriesNCPreferredStockMember" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">4800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-09-30" unitRef="Shares" decimals="INF">4800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-03-26_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_custom_SeriesNCPreferredStockMember" unitRef="Shares" decimals="INF">20000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">2260025066</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-09-30" unitRef="Shares" decimals="INF">1605000246</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">2260025066</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-09-30" unitRef="Shares" decimals="INF">1605000246</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-09-30" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-12-31_custom_SeriesAAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-09-30_custom_SeriesAAPreferredStockMember" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-12-31_custom_SeriesMMember" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-09-30_custom_SeriesMMember" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">800000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-09-30" unitRef="Shares" decimals="INF">800000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">300000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-09-30_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">300000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31_custom_SeriesAAPreferredStockMember" unitRef="Shares" decimals="INF">600000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-09-30_custom_SeriesAAPreferredStockMember" unitRef="Shares" decimals="INF">600000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31_custom_SeriesMMember" unitRef="Shares" decimals="INF">300000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-09-30_custom_SeriesMMember" unitRef="Shares" decimals="INF">300000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31_custom_SeriesAAPreferredStockMember" unitRef="Shares" decimals="INF">50000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-09-30_custom_SeriesAAPreferredStockMember" unitRef="Shares" decimals="INF">50000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31_custom_SeriesMMember" unitRef="Shares" decimals="INF">44000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-09-30_custom_SeriesMMember" unitRef="Shares" decimals="INF">44000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">381768689</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-09-30_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">414147858</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31_custom_SeriesAAPreferredStockMember" unitRef="Shares" decimals="INF">50000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-09-30_custom_SeriesAAPreferredStockMember" unitRef="Shares" decimals="INF">50000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31_custom_SeriesMMember" unitRef="Shares" decimals="INF">44000000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-09-30_custom_SeriesMMember" unitRef="Shares" decimals="INF">44000000</us-gaap:PreferredStockSharesOutstanding>
    <dei:EntityRegistrantName contextRef="From2020-10-01to2020-12-31">Regen BioPharma Inc</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2020-10-01to2020-12-31">0001589150</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2020-10-01to2020-12-31">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-10-01to2020-12-31">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2020-10-01to2020-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-10-01to2020-12-31">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="From2020-10-01to2020-12-31">No</dei:EntityCurrentReportingStatus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-10-01to2020-12-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-10-01to2020-12-31">2021</dei:DocumentFiscalYearFocus>
    <dei:EntityFilerCategory contextRef="From2020-10-01to2020-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-10-01to2020-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntitySmallBusiness contextRef="From2020-10-01to2020-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityShellCompany contextRef="From2020-10-01to2020-12-31">false</dei:EntityShellCompany>
    <us-gaap:AvailableForSaleSecurities contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">19969</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">19969</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">12109</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">7858</us-gaap:AvailableForSaleSecurities>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">16</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">28</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">74298</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">74298</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">113855</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">110486</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">1269041</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">1269041</us-gaap:AccountsPayableCurrent>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-10-01to2020-12-31">No</dei:EntityInteractiveDataCurrent>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="USD" decimals="0">41415</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-09-30_us-gaap_SeriesAPreferredStockMember" unitRef="USD" decimals="0">38177</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-12-31_custom_SeriesAAPreferredStockMember" unitRef="USD" decimals="0">5</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-09-30_custom_SeriesAAPreferredStockMember" unitRef="USD" decimals="0">5</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-12-31_custom_SeriesMMember" unitRef="USD" decimals="0">4400</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-09-30_custom_SeriesMMember" unitRef="USD" decimals="0">4400</us-gaap:PreferredStockValue>
    <dei:EntityFileNumber contextRef="From2020-10-01to2020-12-31">333-191725</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-10-01to2020-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <us-gaap:AdvertisingExpense contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">0</us-gaap:AdvertisingExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2020-10-01to2020-12-31" unitRef="Pure" decimals="INF">1.00</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <RGBP:NetIncomeLossSinceInception contextRef="From2012-10-24to2020-06-30" unitRef="USD" decimals="0">-14917300</RGBP:NetIncomeLossSinceInception>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">62127</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2020-12-31_custom_DavidKoosMember" unitRef="USD" decimals="0">227</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2020-12-31_custom_BSTPartnersMember" unitRef="USD" decimals="0">61900</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2020-12-31_custom_BSTPartnersMember381225750" unitRef="USD" decimals="0">61900</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2020-12-31_custom_DavidKoosMember" unitRef="USD" decimals="0">227</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2020-09-30_custom_DavidKoosMember94604294" unitRef="USD" decimals="0">227</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_March82016Member" unitRef="USD" decimals="0">100000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_April62016Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_September82016Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_September202016Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_October312016Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_October3120162Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_October3120163Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_December222016Member" unitRef="USD" decimals="0">40000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_March12017Member" unitRef="USD" decimals="0">75000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_March92017Member" unitRef="USD" decimals="0">25000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_March132017Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_March312017Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_April192017Member" unitRef="USD" decimals="0">25000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_April1920172Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_May52017Member" unitRef="USD" decimals="0">200000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_May102017Member" unitRef="USD" decimals="0">100000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_May192017Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_June262017Member" unitRef="USD" decimals="0">150000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_July242017Member" unitRef="USD" decimals="0">60000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Aug292017Member" unitRef="USD" decimals="0">25000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Sept222017Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Sept2220172Member" unitRef="USD" decimals="0">100000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Sept252017Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Oct0317Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Oct0417Member" unitRef="USD" decimals="0">40000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Oct1617Member" unitRef="USD" decimals="0">100000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Nov0117Member" unitRef="USD" decimals="0">25000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Nov0120172Member" unitRef="USD" decimals="0">25000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Dec1517Member" unitRef="USD" decimals="0">35000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Dec2017Member" unitRef="USD" decimals="0">100000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Dec20172Member" unitRef="USD" decimals="0">115000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Dec0617Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Jan2418Member" unitRef="USD" decimals="0">25000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_Feb2818Member" unitRef="USD" decimals="0">100000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_May182018Member" unitRef="USD" decimals="0">114000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_July112018Member" unitRef="USD" decimals="0">11500</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_September302018Member" unitRef="USD" decimals="0">350000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_October32018Member" unitRef="USD" decimals="0">63000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_October102018Member" unitRef="USD" decimals="0">75000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_January222019Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_February152019Member" unitRef="USD" decimals="0">50000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_July192019Member" unitRef="USD" decimals="0">100000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_July1920192Member" unitRef="USD" decimals="0">20331</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31_custom_July1920193Member" unitRef="USD" decimals="0">14819</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_March82016Member" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_April62016Member" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_September82016Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_September202016Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_October312016Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_October3120162Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_October3120163Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_December222016Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_March12017Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_March92017Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_March132017Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_March312017Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_April192017Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_April1920172Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_May52017Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_May102017Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_May192017Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_June262017Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_July242017Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Aug292017Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Sept222017Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Sept2220172Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Sept252017Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Oct0317Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Oct0417Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Oct1617Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Nov0117Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Nov0120172Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Dec1517Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Dec2017Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Dec20172Member" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Dec0617Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Jan2418Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_Feb2818Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_May182018Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_July112018Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_September302018Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_October32018Member" unitRef="Pure" decimals="INF">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_October102018Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_January222019Member" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2020-12-31_custom_February152019Member" unitRef="Pure" decimals="INF">0.60</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_March82016Member">2019-03-08</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_April62016Member">2019-04-06</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_September82016Member">2017-09-08</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_September202016Member">2017-09-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_October312016Member">2018-10-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_October3120162Member">2018-10-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_October3120163Member">2018-10-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_December222016Member">2017-12-22</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_March12017Member">2020-03-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_March92017Member">2020-03-09</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_March132017Member">2020-02-24</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_March312017Member">2020-03-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_April192017Member">2020-04-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_April1920172Member">2020-04-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_May52017Member">2020-05-05</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_May102017Member">2020-05-09</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_May192017Member">2020-05-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_June262017Member">2020-06-16</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_July242017Member">2020-07-24</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Sept72017Member">2018-09-07</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Aug292017Member">2020-08-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Sept222017Member">2020-09-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Sept2220172Member">2020-09-22</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Sept252017Member">2020-09-25</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Oct0317Member">2020-10-03</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Oct0417Member">2020-10-04</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Oct1617Member">2020-10-09</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Nov0117Member">2020-11-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Nov0120172Member">2020-11-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Dec1517Member">2020-12-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Dec2017Member">2020-12-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Dec20172Member">2018-12-06</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Dec0617Member">2020-12-06</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Jan2418Member">2020-12-06</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Feb2818Member">2021-02-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_Feb2618Member">2019-02-26</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_May182018Member">2019-02-18</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_July112018Member">2021-05-04</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_August142018Member">2019-08-13</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_September302018Member">2020-09-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_October32018Member">2019-10-03</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_October102018Member">2019-10-11</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_January222019Member">2020-01-22</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_July192019Member">2020-07-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_July1920192Member">2019-07-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-10-01to2020-12-31_custom_July1920193Member">2019-07-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2020-10-01to2020-12-31_custom_March82016Member" unitRef="USD" decimals="0">42600</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2020-10-01to2020-12-31_custom_April62016Member" unitRef="USD" decimals="0">9900</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2020-10-01to2020-12-31_custom_September82016Member" unitRef="USD" decimals="0">50000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2020-10-01to2020-12-31_custom_September202016Member" unitRef="USD" decimals="0">50000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2020-10-01to2020-12-31_custom_October312016Member" unitRef="USD" decimals="0">50000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2020-10-01to2020-12-31_custom_October3120162Member" unitRef="USD" decimals="0">50000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2020-10-01to2020-12-31_custom_October3120163Member" unitRef="USD" decimals="0">50000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2020-10-01to2020-12-31_custom_December222016Member" unitRef="USD" decimals="0">40000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2020-10-01to2020-12-31_custom_September302018Member" unitRef="USD" decimals="0">350000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_March82016Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_April62016Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_September82016Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_September202016Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_October312016Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_October3120162Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_October3120163Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_December222016Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_March12017Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_March92017Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_March132017Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_March312017Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_April192017Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_April1920172Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_May52017Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_May102017Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_May192017Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_June262017Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_July242017Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_Aug292017Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_Sept222017Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_Sept2220172Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_Sept252017Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_Oct0317Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_Oct0417Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_Oct1617Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_Nov0117Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_Dec1517Member" unitRef="USD" decimals="0">383</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_Dec2017Member" unitRef="USD" decimals="0">1551</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_Dec20172Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_Dec0617Member" unitRef="USD" decimals="0">136</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_Jan2418Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_Feb2818Member" unitRef="USD" decimals="0">6843</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_May182018Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_July112018Member" unitRef="USD" decimals="0">1431</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_September302018Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_October32018Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_October102018Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_January222019Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_February152019Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_July192019Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_July1920192Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_custom_July1920193Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal contextRef="From2020-10-01to2020-12-31_custom_September302018Member" unitRef="USD" decimals="0">14242</us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_March82016Member" unitRef="USD" decimals="0">100000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_April62016Member" unitRef="USD" decimals="0">50000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_September82016Member" unitRef="USD" decimals="0">50000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_September202016Member" unitRef="USD" decimals="0">50000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_October312016Member" unitRef="USD" decimals="0">50000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_October3120162Member" unitRef="USD" decimals="0">50000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_October3120163Member" unitRef="USD" decimals="0">50000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_December222016Member" unitRef="USD" decimals="0">40000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_March12017Member" unitRef="USD" decimals="0">75000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_March92017Member" unitRef="USD" decimals="0">25000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_March132017Member" unitRef="USD" decimals="0">50000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_March312017Member" unitRef="USD" decimals="0">50000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_April192017Member" unitRef="USD" decimals="0">25000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_April1920172Member" unitRef="USD" decimals="0">50000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_May52017Member" unitRef="USD" decimals="0">200000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_May102017Member" unitRef="USD" decimals="0">100000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_May192017Member" unitRef="USD" decimals="0">50000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_June262017Member" unitRef="USD" decimals="0">150000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_July242017Member" unitRef="USD" decimals="0">60000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Aug292017Member" unitRef="USD" decimals="0">25000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Sept222017Member" unitRef="USD" decimals="0">50000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Sept2220172Member" unitRef="USD" decimals="0">100000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Sept252017Member" unitRef="USD" decimals="0">50000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Oct0317Member" unitRef="USD" decimals="0">50000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Oct0417Member" unitRef="USD" decimals="0">40000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Oct1617Member" unitRef="USD" decimals="0">100000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Nov0117Member" unitRef="USD" decimals="0">25000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Nov0120172Member" unitRef="USD" decimals="0">25000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Dec1517Member" unitRef="USD" decimals="0">35000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Dec2017Member" unitRef="USD" decimals="0">100000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Dec20172Member" unitRef="USD" decimals="0">31893</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Dec0617Member" unitRef="USD" decimals="0">50000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Jan2418Member" unitRef="USD" decimals="0">25000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_Feb2818Member" unitRef="USD" decimals="0">100000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_May182018Member" unitRef="USD" decimals="0">65149</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_July112018Member" unitRef="USD" decimals="0">11500</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_September302018Member" unitRef="USD" decimals="0">10000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_October32018Member" unitRef="USD" decimals="0">23260</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_October102018Member" unitRef="USD" decimals="0">50500</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_January222019Member" unitRef="USD" decimals="0">19607</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_February152019Member" unitRef="USD" decimals="0">19018</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_July192019Member" unitRef="USD" decimals="0">100000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_July1920192Member" unitRef="USD" decimals="0">20331</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31_custom_July1920193Member" unitRef="USD" decimals="0">14819</us-gaap:NotesPayableCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_March12017Member" unitRef="USD" decimals="0">150000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_March92017Member" unitRef="USD" decimals="0">10000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_March132017Member" unitRef="USD" decimals="0">20000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_March312017Member" unitRef="USD" decimals="0">20000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_April192017Member" unitRef="USD" decimals="0">10000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_April1920172Member" unitRef="USD" decimals="0">10000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_May52017Member" unitRef="USD" decimals="0">80000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_May102017Member" unitRef="USD" decimals="0">40000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_May192017Member" unitRef="USD" decimals="0">20000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_June262017Member" unitRef="USD" decimals="0">60000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_July242017Member" unitRef="USD" decimals="0">24000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Aug292017Member" unitRef="USD" decimals="0">10000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Sept222017Member" unitRef="USD" decimals="0">20000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Sept2220172Member" unitRef="USD" decimals="0">40000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Sept252017Member" unitRef="USD" decimals="0">20000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Oct0317Member" unitRef="USD" decimals="0">66667</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Oct0417Member" unitRef="USD" decimals="0">16000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Oct1617Member" unitRef="USD" decimals="0">40000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Nov0117Member" unitRef="USD" decimals="0">10000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Nov0120172Member" unitRef="USD" decimals="0">10000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Dec1517Member" unitRef="USD" decimals="0">14000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Dec2017Member" unitRef="USD" decimals="0">40000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Dec20172Member" unitRef="USD" decimals="0">115000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Dec0617Member" unitRef="USD" decimals="0">20000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Jan2418Member" unitRef="USD" decimals="0">10000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_Feb2818Member" unitRef="USD" decimals="0">40000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_May182018Member" unitRef="USD" decimals="0">27145</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_July112018Member" unitRef="USD" decimals="0">4600</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_September302018Member" unitRef="USD" decimals="0">350000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_October32018Member" unitRef="USD" decimals="0">11928</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_October102018Member" unitRef="USD" decimals="0">7307</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_January222019Member" unitRef="USD" decimals="0">8169</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_February152019Member" unitRef="USD" decimals="0">7924</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_July192019Member" unitRef="USD" decimals="0">55555</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_July1920192Member" unitRef="USD" decimals="0">7819</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_July1920193Member" unitRef="USD" decimals="0">6174</us-gaap:DerivativeLiabilitiesCurrent>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_March82016Member" unitRef="USD" decimals="0">100000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_April62016Member" unitRef="USD" decimals="0">50000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_September82016Member" unitRef="USD" decimals="0">50000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_September202016Member" unitRef="USD" decimals="0">50000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_October312016Member" unitRef="USD" decimals="0">50000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_October3120162Member" unitRef="USD" decimals="0">50000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_October3120163Member" unitRef="USD" decimals="0">50000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_December222016Member" unitRef="USD" decimals="0">40000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_March12017Member" unitRef="USD" decimals="0">75000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_March92017Member" unitRef="USD" decimals="0">25000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_March132017Member" unitRef="USD" decimals="0">25000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_March312017Member" unitRef="USD" decimals="0">50000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_April192017Member" unitRef="USD" decimals="0">25000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_April1920172Member" unitRef="USD" decimals="0">50000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_May52017Member" unitRef="USD" decimals="0">200000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_May102017Member" unitRef="USD" decimals="0">100000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_May192017Member" unitRef="USD" decimals="0">50000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_June262017Member" unitRef="USD" decimals="0">150000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_July242017Member" unitRef="USD" decimals="0">60000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Aug292017Member" unitRef="USD" decimals="0">25000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Sept222017Member" unitRef="USD" decimals="0">50000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Sept2220172Member" unitRef="USD" decimals="0">100000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Sept252017Member" unitRef="USD" decimals="0">50000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Oct0317Member" unitRef="USD" decimals="0">50000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Oct0417Member" unitRef="USD" decimals="0">40000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Oct1617Member" unitRef="USD" decimals="0">100000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Nov0117Member" unitRef="USD" decimals="0">25000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Nov0120172Member" unitRef="USD" decimals="0">25000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Dec1517Member" unitRef="USD" decimals="0">35000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Dec2017Member" unitRef="USD" decimals="0">100000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Dec20172Member" unitRef="USD" decimals="0">100000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Dec0617Member" unitRef="USD" decimals="0">50000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Jan2418Member" unitRef="USD" decimals="0">25000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_Feb2818Member" unitRef="USD" decimals="0">100000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_May182018Member" unitRef="USD" decimals="0">100000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_July112018Member" unitRef="USD" decimals="0">11500</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_September302018Member" unitRef="USD" decimals="0">350000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_October32018Member" unitRef="USD" decimals="0">60000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_October102018Member" unitRef="USD" decimals="0">71250</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_January222019Member" unitRef="USD" decimals="0">47500</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_February152019Member" unitRef="USD" decimals="0">47500</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_July192019Member" unitRef="USD" decimals="0">95000</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_July1920192Member" unitRef="USD" decimals="0">18831</RGBP:CashIssuedForConvertibleNote>
    <RGBP:CashIssuedForConvertibleNote contextRef="AsOf2020-12-31_custom_July1920193Member" unitRef="USD" decimals="0">13319</RGBP:CashIssuedForConvertibleNote>
    <RGBP:OriginalIssueDiscount contextRef="AsOf2020-12-31_custom_Dec20172Member" unitRef="USD" decimals="0">1750</RGBP:OriginalIssueDiscount>
    <RGBP:OriginalIssueDiscount contextRef="AsOf2020-12-31_custom_May182018Member" unitRef="USD" decimals="0">14000</RGBP:OriginalIssueDiscount>
    <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="From2020-10-01to2020-12-31_us-gaap_SeriesAMember" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockDividendRatePerDollarAmount>
    <us-gaap:PreferredStockVotingRights contextRef="From2020-10-01to2020-12-31_custom_SeriesAAPreferredStockMember">Series AA Preferred Stock</us-gaap:PreferredStockVotingRights>
    <us-gaap:PreferredStockVotingRights contextRef="From2020-10-01to2020-12-31_custom_SeriesMMember">On January 10, 2017 Regen Biopharma, Inc. (&#8220;Regen&#8221;) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series M Preferred Stock" (hereinafter referred to as "Series M Preferred Stock").</us-gaap:PreferredStockVotingRights>
    <us-gaap:PreferredStockVotingRights contextRef="From2020-10-01to2020-12-31_us-gaap_SeriesAMember">Series A Preferred Stock</us-gaap:PreferredStockVotingRights>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-10-01to2020-10-28_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">80065846</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-11-01to2020-11-06_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">83934153</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-12-02to2020-12-11_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">87020000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-12-02to2020-12-16_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">6437153</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-12-03to2020-12-16_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">88158923</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-12-02to2020-12-17_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">83216917</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-12-01to2020-12-23_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">108444444</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-12-01to2020-12-31_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">117837384</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-01-01to2021-01-28_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">85900000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-02-01to2021-02-23_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">88000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-02-01to2021-02-24_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">82759286</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-03-01to2021-03-02_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">119269538</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-03-01to2021-03-18_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">70000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-03-01to2021-03-31_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">40000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-04-01to2021-04-12_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">85000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-04-01to2021-04-13_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">83636833</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-04-02to2021-04-13_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">32968042</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-04-01to2021-04-15_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">146452000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-04-02to2021-04-15_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">49482000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-04-01to2021-04-16_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">70755885</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-04-02to2021-04-16_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">90311411</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-04-01to2021-04-21_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">163814000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-04-01to2021-04-28_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">28784167</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-05-01to2021-05-03_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">33012555</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-05-01to2021-05-05_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">27753016</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-12-01to2020-12-17_us-gaap_ConvertibleDebtMember_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">32379169</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2020-10-01to2020-10-28_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3752</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2020-11-01to2020-11-06_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3900</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2020-12-02to2020-12-11_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">7300</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2020-12-02to2020-12-16_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">429</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2020-12-03to2020-12-16_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4030</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2020-12-02to2020-12-17_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">8200</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2020-12-01to2020-12-23_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">16000</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2020-12-01to2020-12-31_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5330</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-01-01to2021-01-28_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5154</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-02-01to2021-02-23_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4400</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-02-01to2021-02-24_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">30000</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-03-01to2021-03-02_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5260</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-03-01to2021-03-18_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3415</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-03-01to2021-03-31_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1926</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-04-01to2021-04-12_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3111</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-04-01to2021-04-13_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3511</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-04-02to2021-04-13_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">19000</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-04-01to2021-04-15_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1416</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-04-02to2021-04-15_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2288</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-04-01to2021-04-16_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">47000</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-04-02to2021-04-16_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4238</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-04-01to2021-04-21_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">7564</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-04-01to2021-04-28_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">22000</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-05-01to2021-05-03_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1416</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2021-05-01to2021-05-05_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1187</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities contextRef="From2020-12-01to2020-12-17_us-gaap_ConvertibleDebtMember_us-gaap_SeriesAPreferredStockMember" unitRef="USD" decimals="0">13000</RGBP:StockIssuedDuringPeriodValuesConversionOfConvertibleSecurities>
    <us-gaap:InterestExpenseDebt contextRef="From2020-10-01to2020-10-28_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1452</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-11-01to2020-11-06_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1555</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-12-02to2020-12-11_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3142</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-12-02to2020-12-16_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">236</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-12-03to2020-12-16_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1700</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-12-02to2020-12-17_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1786</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-12-01to2020-12-23_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3250</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-12-01to2020-12-31_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2329</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-02-01to2021-02-24_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4758</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-03-01to2021-03-02_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2492</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-03-01to2021-03-18_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">84</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-03-01to2021-03-31_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">74</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-04-01to2021-04-12_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">49</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-04-01to2021-04-13_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1508</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-04-02to2021-04-13_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4736</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-04-01to2021-04-15_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">680</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-04-02to2021-04-15_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">680</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-04-01to2021-04-16_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">8189</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-04-02to2021-04-16_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">17</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-04-01to2021-04-21_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2264</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-04-01to2021-04-28_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3905</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-05-01to2021-05-03_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">729</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2021-05-01to2021-05-05_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_us-gaap_CommonStockMember" unitRef="USD" decimals="0">616</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="From2020-12-01to2020-12-17_us-gaap_ConvertibleDebtMember_us-gaap_SeriesAPreferredStockMember" unitRef="USD" decimals="0">8046</us-gaap:InterestExpenseDebt>
    <RGBP:FairValueOfIntellectualProperty contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">1500</RGBP:FairValueOfIntellectualProperty>
    <RGBP:FairValueOfIntellectualProperty contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">1500</RGBP:FairValueOfIntellectualProperty>
    <us-gaap:DueFromEmployees contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">1071</us-gaap:DueFromEmployees>
    <us-gaap:DueFromEmployees contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">1071</us-gaap:DueFromEmployees>
    <us-gaap:ReceivablesNetCurrent contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">64400</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">64400</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AccruedInvestmentIncomeReceivable contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">20274</us-gaap:AccruedInvestmentIncomeReceivable>
    <us-gaap:AccruedInvestmentIncomeReceivable contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">20274</us-gaap:AccruedInvestmentIncomeReceivable>
    <us-gaap:Investments contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">593357</us-gaap:Investments>
    <us-gaap:Investments contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">593357</us-gaap:Investments>
    <RGBP:ConvertibleNoteReceivable contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">10000</RGBP:ConvertibleNoteReceivable>
    <RGBP:ConvertibleNoteReceivable contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">10000</RGBP:ConvertibleNoteReceivable>
    <us-gaap:NotesPayable contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">500000</us-gaap:NotesPayable>
    <RGBP:AccruedExpensesRelated contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">89529</RGBP:AccruedExpensesRelated>
    <RGBP:AccruedExpensesRelated contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">89529</RGBP:AccruedExpensesRelated>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">203037</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">203037</us-gaap:AccruedLiabilitiesCurrent>
    <RGBP:EnterpriseValue contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">2826507</RGBP:EnterpriseValue>
    <RGBP:EnterpriseValue contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">2826507</RGBP:EnterpriseValue>
    <us-gaap:DebtCurrent contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">2061607</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">2061607</us-gaap:DebtCurrent>
    <RGBP:PortionOfEnterpriseValueAttributableToShareholders contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">764900</RGBP:PortionOfEnterpriseValueAttributableToShareholders>
    <RGBP:PortionOfEnterpriseValueAttributableToShareholders contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">764900</RGBP:PortionOfEnterpriseValueAttributableToShareholders>
    <RGBP:InvestmentSecuritiesBasis contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">13124</RGBP:InvestmentSecuritiesBasis>
    <RGBP:InvestmentSecuritiesBasis contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">5741</RGBP:InvestmentSecuritiesBasis>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="From2020-10-01to2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <RGBP:NumberOfSharesIssuedForPropertyDividend contextRef="From2018-05-30to2018-06-11_custom_ZanderTherapeuticsMember" unitRef="Shares" decimals="INF">470588</RGBP:NumberOfSharesIssuedForPropertyDividend>
    <RGBP:NumberOfSharesIssuedForPropertyDividend contextRef="From2020-10-01to2020-12-31_custom_ZanderTherapeuticsMember" unitRef="Shares" decimals="INF">470588</RGBP:NumberOfSharesIssuedForPropertyDividend>
    <RGBP:NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest contextRef="From2020-10-01to2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="Shares" decimals="INF">725000</RGBP:NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest>
    <RGBP:NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest contextRef="From2018-11-01to2018-11-29_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="Shares" decimals="INF">725000</RGBP:NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest>
    <RGBP:SharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterestValue contextRef="From2018-11-01to2018-11-29_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">13124</RGBP:SharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterestValue>
    <RGBP:FairValuePerShare contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USDPShares" decimals="INF">0.0167</RGBP:FairValuePerShare>
    <RGBP:FairValuePerShare contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USDPShares" decimals="INF">0.0167</RGBP:FairValuePerShare>
    <RGBP:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax contextRef="AsOf2020-12-31_custom_SeriesMMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">-1104</RGBP:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax>
    <RGBP:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax contextRef="AsOf2020-12-31_us-gaap_CommonStockMember_custom_ZanderTherapeuticsMember" unitRef="USD" decimals="0">2118</RGBP:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2020-10-01to2020-12-31" unitRef="Pure" decimals="INF">0.0175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2020-10-01to2020-12-31" unitRef="Pure" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="From2019-10-01to2020-09-30_custom_DavidKoosMember" unitRef="Pure" decimals="INF">0.15</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LoansPayable contextRef="AsOf2019-10-02_custom_BSTPartnersMember" unitRef="USD" decimals="0">6000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2019-10-04_custom_BSTPartnersMember" unitRef="USD" decimals="0">2300</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2019-10-24_custom_BSTPartnersMember" unitRef="USD" decimals="0">7400</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2019-10-25_custom_BSTPartnersMember" unitRef="USD" decimals="0">1000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2019-10-31_custom_BSTPartnersMember" unitRef="USD" decimals="0">2000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2019-11-06_custom_BSTPartnersMember" unitRef="USD" decimals="0">1500</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2019-11-08_custom_BSTPartnersMember" unitRef="USD" decimals="0">6000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2019-11-15_custom_BSTPartnersMember" unitRef="USD" decimals="0">2000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2019-11-26_custom_BSTPartnersMember" unitRef="USD" decimals="0">2100</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2019-12-02_custom_BSTPartnersMember" unitRef="USD" decimals="0">1000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2019-12-17_custom_BSTPartnersMember" unitRef="USD" decimals="0">1300</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2020-01-02_custom_BSTPartnersMember" unitRef="USD" decimals="0">1400</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2020-01-10_custom_BSTPartnersMember" unitRef="USD" decimals="0">2500</us-gaap:LoansPayable>
    <us-gaap:LoansPayable contextRef="AsOf2020-01-16_custom_BSTPartnersMember" unitRef="USD" decimals="0">1400</us-gaap:LoansPayable>
    <us-gaap:RelatedPartyTransactionRate contextRef="From2019-10-01to2019-10-02_custom_BSTPartnersMember" unitRef="Pure" decimals="INF">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="From2019-10-01to2019-10-04_custom_BSTPartnersMember" unitRef="Pure" decimals="INF">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="From2019-10-01to2019-10-24_custom_BSTPartnersMember" unitRef="Pure" decimals="INF">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="From2019-10-01to2019-10-25_custom_BSTPartnersMember" unitRef="Pure" decimals="INF">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="From2019-10-01to2019-10-31_custom_BSTPartnersMember" unitRef="Pure" decimals="INF">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="From2019-11-01to2019-11-06_custom_BSTPartnersMember" unitRef="Pure" decimals="INF">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="From2019-11-01to2019-11-08_custom_BSTPartnersMember" unitRef="Pure" decimals="INF">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="From2019-11-01to2019-11-15_custom_BSTPartnersMember" unitRef="Pure" decimals="INF">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="From2019-11-01to2019-11-26_custom_BSTPartnersMember" unitRef="Pure" decimals="INF">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="From2019-12-01to2019-12-02_custom_BSTPartnersMember" unitRef="Pure" decimals="INF">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="From2019-12-01to2019-12-17_custom_BSTPartnersMember" unitRef="Pure" decimals="INF">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="From2020-01-01to2020-01-02_custom_BSTPartnersMember" unitRef="Pure" decimals="INF">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="From2020-01-01to2020-01-10_custom_BSTPartnersMember" unitRef="Pure" decimals="INF">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionRate contextRef="From2020-01-01to2020-01-16_custom_BSTPartnersMember" unitRef="Pure" decimals="INF">0.10</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear contextRef="From2019-10-01to2019-10-02_custom_BSTPartnersMember">2020-10-02</us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear>
    <us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear contextRef="From2019-10-01to2019-10-04_custom_BSTPartnersMember">2020-10-04</us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear>
    <us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear contextRef="From2019-10-01to2019-10-24_custom_BSTPartnersMember">2020-10-24</us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear>
    <us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear contextRef="From2019-10-01to2019-10-25_custom_BSTPartnersMember">2020-10-25</us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear>
    <us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear contextRef="From2019-10-01to2019-10-31_custom_BSTPartnersMember">2020-10-31</us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear>
    <us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear contextRef="From2019-11-01to2019-11-06_custom_BSTPartnersMember">2020-11-06</us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear>
    <us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear contextRef="From2019-11-01to2019-11-08_custom_BSTPartnersMember">2020-11-08</us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear>
    <us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear contextRef="From2019-11-01to2019-11-15_custom_BSTPartnersMember">2020-11-15</us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear>
    <us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear contextRef="From2019-11-01to2019-11-26_custom_BSTPartnersMember">2020-11-26</us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear>
    <us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear contextRef="From2019-12-01to2019-12-02_custom_BSTPartnersMember">2020-12-02</us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear>
    <us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear contextRef="From2019-12-01to2019-12-17_custom_BSTPartnersMember">2020-12-18</us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear>
    <us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear contextRef="From2020-01-01to2020-01-02_custom_BSTPartnersMember">2021-01-02</us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear>
    <us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear contextRef="From2020-01-01to2020-01-10_custom_BSTPartnersMember">2021-01-10</us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear>
    <us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear contextRef="From2020-01-01to2020-01-16_custom_BSTPartnersMember">2021-01-16</us-gaap:DebtConversionOriginalDebtDueDateOfDebtDayMonthAndYear>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">226000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">160498</us-gaap:CommonStockValue>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">150602</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">123189</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">-5581256</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">-7334998</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">-14917300</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">-16583666</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:OtherAdditionalCapital contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">733576</us-gaap:OtherAdditionalCapital>
    <us-gaap:OtherAdditionalCapital contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">731711</us-gaap:OtherAdditionalCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">8330647</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">8313877</us-gaap:AdditionalPaidInCapital>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">-18480</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-134738</us-gaap:OperatingIncomeLoss>
    <us-gaap:CostsAndExpenses contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">45905</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">162163</us-gaap:CostsAndExpenses>
    <us-gaap:LeaseAndRentalExpense contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">15000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ProfessionalFees contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">35286</us-gaap:ProfessionalFees>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">44778</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">104358</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">1127</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">7519</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:Revenues contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">27425</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">27425</us-gaap:Revenues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-10-01to2020-12-31_srt_MinimumMember">P4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-10-01to2020-12-31_srt_MaximumMember">P1Y10M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">5731858</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">7458187</us-gaap:Liabilities>
    <RGBP:ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNonCurrent contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">0</RGBP:ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNonCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">5731858</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">7458187</us-gaap:LiabilitiesCurrent>
    <RGBP:ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">20068</RGBP:ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount>
    <RGBP:ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">19050</RGBP:ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">2503543</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">2522716</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">832726</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">2634215</us-gaap:DerivativeLiabilities>
    <RGBP:DueToInvestor contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">20000</RGBP:DueToInvestor>
    <RGBP:DueToInvestor contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">20000</RGBP:DueToInvestor>
    <us-gaap:BankOverdrafts contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">1000</us-gaap:BankOverdrafts>
    <us-gaap:BankOverdrafts contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">1000</us-gaap:BankOverdrafts>
    <RGBP:OtherAccruedExpenses contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">41423</RGBP:OtherAccruedExpenses>
    <RGBP:OtherAccruedExpenses contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">41423</RGBP:OtherAccruedExpenses>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">1229819</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">1189319</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <RGBP:AccruedRent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">23548</RGBP:AccruedRent>
    <RGBP:AccruedRent contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">23548</RGBP:AccruedRent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">879507</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">830061</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">4241</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">4241</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:NotesAndLoansPayable contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">62127</us-gaap:NotesAndLoansPayable>
    <us-gaap:NotesAndLoansPayable contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">62127</us-gaap:NotesAndLoansPayable>
    <us-gaap:Assets contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">150602</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">123189</us-gaap:Assets>
    <us-gaap:OtherAssets contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">19969</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">19969</us-gaap:OtherAssets>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">130633</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">103220</us-gaap:AssetsCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">130617</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">103192</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:Cash contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">0</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">0</us-gaap:Cash>
    <RGBP:NumberOfNonVotingConvertiblePreferredStockSold contextRef="From2021-03-01to2021-03-26_us-gaap_SubsequentEventMember_us-gaap_ConvertibleDebtMember_custom_SeriesNCPreferredStockMember" unitRef="Shares" decimals="INF">500000</RGBP:NumberOfNonVotingConvertiblePreferredStockSold>
    <RGBP:InterestExpenseAttributableToAmortizationOfDiscount contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">-36717</RGBP:InterestExpenseAttributableToAmortizationOfDiscount>
    <RGBP:InterestExpenseAttributableToAmortizationOfDiscount contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-200355</RGBP:InterestExpenseAttributableToAmortizationOfDiscount>
    <us-gaap:OtherNoncashIncomeExpense contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">1684847</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">3217518</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">1794776</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">3506496</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2020-10-01to2020-12-31" unitRef="Shares" decimals="INF">1769079104</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2019-10-01to2019-12-31" unitRef="Shares" decimals="INF">835956877</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-10-01to2020-12-31" unitRef="USDPShares" decimals="INF">0</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-10-01to2019-12-31" unitRef="USDPShares" decimals="INF">0.003</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">1385417</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">2413805</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <RGBP:CommonStockIssuedForExpenses contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">-159</RGBP:CommonStockIssuedForExpenses>
    <RGBP:CommonStockIssuedForExpenses contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-2000</RGBP:CommonStockIssuedForExpenses>
    <RGBP:PreferredStockIssued2 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-600</RGBP:PreferredStockIssued2>
    <us-gaap:NetIncomeLoss contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">1666367</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">3082768</us-gaap:NetIncomeLoss>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">36717</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">200355</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">3369</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">7156</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">27425</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-48476</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">113712</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">189298</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">-12</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-12</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <RGBP:IncreaseDecreaseInContributedCapital contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">1865</RGBP:IncreaseDecreaseInContributedCapital>
    <RGBP:IncreaseDecreaseInContributedCapital contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">133</RGBP:IncreaseDecreaseInContributedCapital>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">-1794776</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-3506496</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">24302</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <RGBP:IncreasedecreaseInSaleOfInvestmentSecurities contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">0</RGBP:IncreasedecreaseInSaleOfInvestmentSecurities>
    <RGBP:IncreasedecreaseInSaleOfInvestmentSecurities contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">0</RGBP:IncreasedecreaseInSaleOfInvestmentSecurities>
    <us-gaap:IncreaseDecreaseInNotesPayableCurrent contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInNotesPayableCurrent>
    <us-gaap:IncreaseDecreaseInNotesPayableCurrent contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-31800</us-gaap:IncreaseDecreaseInNotesPayableCurrent>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-31800</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-7498</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <RGBP:CommonSharesIssuedForDebt contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">48941</RGBP:CommonSharesIssuedForDebt>
    <RGBP:CommonSharesIssuedForDebt contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">106064</RGBP:CommonSharesIssuedForDebt>
    <RGBP:PreferredSharesIssuedForDebt contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">13000</RGBP:PreferredSharesIssuedForDebt>
    <RGBP:CommonSharesIssuedForInterest contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">15721</RGBP:CommonSharesIssuedForInterest>
    <RGBP:CommonSharesIssuedForInterest contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">17782</RGBP:CommonSharesIssuedForInterest>
    <RGBP:PreferredSharesIssuedForInterest contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">8046</RGBP:PreferredSharesIssuedForInterest>
    <RGBP:PreferredSharesIssuedForInterest contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">0</RGBP:PreferredSharesIssuedForInterest>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">7855</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">357</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaid contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">0</us-gaap:InterestPaid>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">-73212</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-88623</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-09-30_custom_SeriesAPreferredStocksMember" unitRef="Shares" decimals="INF">348376230</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_custom_SeriesAPreferredStocksMember" unitRef="Shares" decimals="INF">348376230</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-09-30_custom_SeriesAAPreferredStockMember" unitRef="Shares" decimals="INF">50000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_custom_SeriesAAPreferredStockMember" unitRef="Shares" decimals="INF">50000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">600001406</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1422306114</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-09-30_custom_SeriesMPreferredStockMember" unitRef="Shares" decimals="INF">38000000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_custom_SeriesMPreferredStockMember" unitRef="Shares" decimals="INF">44000000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-09-30_custom_SeriesAPreferredStocksMember" unitRef="Shares" decimals="INF">381768689</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_custom_SeriesAPreferredStocksMember" unitRef="Shares" decimals="INF">414147858</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-09-30_custom_SeriesAAPreferredStockMember68709765" unitRef="Shares" decimals="INF">50000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_custom_SeriesAAPreferredStockMember68493578" unitRef="Shares" decimals="INF">50000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1605000246</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2260025066</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-09-30_custom_SeriesMPreferredStockMember" unitRef="Shares" decimals="INF">44000000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_custom_SeriesMPreferredStockMember" unitRef="Shares" decimals="INF">44000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">-5581256</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">-7334998</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">-10908795</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">-7699447</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_custom_SeriesAPreferredStocksMember" unitRef="USD" decimals="0">34838</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_custom_SeriesAPreferredStocksMember" unitRef="USD" decimals="0">34838</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_custom_SeriesAAPreferredStockMember" unitRef="USD" decimals="0">5</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_custom_SeriesAAPreferredStockMember" unitRef="USD" decimals="0">5</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">59998</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">142228</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_custom_SeriesMPreferredStockMember" unitRef="USD" decimals="0">3800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_custom_SeriesMPreferredStockMember" unitRef="USD" decimals="0">4400</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">8261993</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">8305609</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-19998086</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-16915318</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_custom_ContributedCapitalMember" unitRef="USD" decimals="0">728658</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_custom_ContributedCapitalMember" unitRef="USD" decimals="0">728791</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30_custom_SeriesAPreferredStocksMember" unitRef="USD" decimals="0">38177</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_custom_SeriesAPreferredStocksMember" unitRef="USD" decimals="0">41415</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30_custom_SeriesAAPreferredStockMember68709765" unitRef="USD" decimals="0">5</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_custom_SeriesAAPreferredStockMember68493578" unitRef="USD" decimals="0">5</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">160498</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">226001</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30_custom_SeriesMPreferredStockMember" unitRef="USD" decimals="0">4400</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_custom_SeriesMPreferredStockMember" unitRef="USD" decimals="0">4400</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">8313876</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">8330646</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-16583666</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-14917299</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30_custom_ContributedCapitalMember" unitRef="USD" decimals="0">731711</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_custom_ContributedCapitalMember" unitRef="USD" decimals="0">733576</us-gaap:StockholdersEquity>
    <RGBP:SharesIssuedForDebtShares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">15100608</RGBP:SharesIssuedForDebtShares>
    <RGBP:SharesIssuedForDebtShares contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">57726183</RGBP:SharesIssuedForDebtShares>
    <RGBP:SharesIssuedForDebtAmount contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">3752</RGBP:SharesIssuedForDebtAmount>
    <RGBP:SharesIssuedForDebtAmount contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">4907</RGBP:SharesIssuedForDebtAmount>
    <RGBP:SharesIssuedForDebtAmount contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1510</RGBP:SharesIssuedForDebtAmount>
    <RGBP:SharesIssuedForDebtAmount contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3397</RGBP:SharesIssuedForDebtAmount>
    <RGBP:SharesIssuedForDebtAmount contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5773</RGBP:SharesIssuedForDebtAmount>
    <RGBP:SharesIssuedForDebtAmount contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-2021</RGBP:SharesIssuedForDebtAmount>
    <RGBP:SharesIssuedForServicesShares contextRef="From2019-10-01to2019-12-31_custom_SeriesMPreferredStockMember" unitRef="Shares" decimals="INF">6000000</RGBP:SharesIssuedForServicesShares>
    <RGBP:SharesIssuedForServicesValue contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">600</RGBP:SharesIssuedForServicesValue>
    <RGBP:SharesIssuedForServicesValue contextRef="From2019-10-01to2019-12-31_custom_SeriesMPreferredStockMember" unitRef="USD" decimals="0">600</RGBP:SharesIssuedForServicesValue>
    <RGBP:SharesIssuedForInterestShares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4376007</RGBP:SharesIssuedForInterestShares>
    <RGBP:SharesIssuedForInterestShares contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">22339663</RGBP:SharesIssuedForInterestShares>
    <RGBP:SharesIssuedForInterestValue contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">1452</RGBP:SharesIssuedForInterestValue>
    <RGBP:SharesIssuedForInterestValue contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">1422</RGBP:SharesIssuedForInterestValue>
    <RGBP:SharesIssuedForInterestValue contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">438</RGBP:SharesIssuedForInterestValue>
    <RGBP:SharesIssuedForInterestValue contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">984</RGBP:SharesIssuedForInterestValue>
    <RGBP:SharesIssuedForInterestValue contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2234</RGBP:SharesIssuedForInterestValue>
    <RGBP:SharesIssuedForInterestValue contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-782</RGBP:SharesIssuedForInterestValue>
    <RGBP:SharesIssuedForFeesShares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5555556</RGBP:SharesIssuedForFeesShares>
    <RGBP:SharesIssuedForFeesValue contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">500</RGBP:SharesIssuedForFeesValue>
    <RGBP:SharesIssuedForFeesValue contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">556</RGBP:SharesIssuedForFeesValue>
    <RGBP:SharesIssuedForFeesValue contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-56</RGBP:SharesIssuedForFeesValue>
    <RGBP:SharesIssuedForInterestShares18 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4217031</RGBP:SharesIssuedForInterestShares18>
    <RGBP:SharesIssuedForInterestShares18 contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">23926234</RGBP:SharesIssuedForInterestShares18>
    <RGBP:SharesIssuedForInterestAmount18 contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">1555</RGBP:SharesIssuedForInterestAmount18>
    <RGBP:SharesIssuedForInterestAmount18 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">1518</RGBP:SharesIssuedForInterestAmount18>
    <RGBP:SharesIssuedForInterestAmount18 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">422</RGBP:SharesIssuedForInterestAmount18>
    <RGBP:SharesIssuedForInterestAmount18 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1096</RGBP:SharesIssuedForInterestAmount18>
    <RGBP:SharesIssuedForInterestAmount18 contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2393</RGBP:SharesIssuedForInterestAmount18>
    <RGBP:SharesIssuedForInterestAmount18 contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-838</RGBP:SharesIssuedForInterestAmount18>
    <RGBP:SharesIssuedForInterestShares19 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">30946444</RGBP:SharesIssuedForInterestShares19>
    <RGBP:SharesIssuedForInterestShares19 contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">26185501</RGBP:SharesIssuedForInterestShares19>
    <RGBP:SharesIssuedForInterestAmount19 contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">3142</RGBP:SharesIssuedForInterestAmount19>
    <RGBP:SharesIssuedForInterestAmount19 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">2785</RGBP:SharesIssuedForInterestAmount19>
    <RGBP:SharesIssuedForInterestAmount19 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3095</RGBP:SharesIssuedForInterestAmount19>
    <RGBP:SharesIssuedForInterestAmount19 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-310</RGBP:SharesIssuedForInterestAmount19>
    <RGBP:SharesIssuedForInterestAmount19 contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2619</RGBP:SharesIssuedForInterestAmount19>
    <RGBP:SharesIssuedForInterestAmount19 contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">523</RGBP:SharesIssuedForInterestAmount19>
    <RGBP:SharesIssuedForDebt1Shares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">20834497</RGBP:SharesIssuedForDebt1Shares>
    <RGBP:SharesIssuedForDebt1Shares contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">60007919</RGBP:SharesIssuedForDebt1Shares>
    <RGBP:SharesIssuedForDebt1Amount contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">3900</RGBP:SharesIssuedForDebt1Amount>
    <RGBP:SharesIssuedForDebt1Amount contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">10000</RGBP:SharesIssuedForDebt1Amount>
    <RGBP:SharesIssuedForDebt1Amount contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2083</RGBP:SharesIssuedForDebt1Amount>
    <RGBP:SharesIssuedForDebt1Amount contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">7917</RGBP:SharesIssuedForDebt1Amount>
    <RGBP:SharesIssuedForDebt1Amount contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">6001</RGBP:SharesIssuedForDebt1Amount>
    <RGBP:SharesIssuedForDebt1Amount contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-2101</RGBP:SharesIssuedForDebt1Amount>
    <RGBP:SharesIssuedForInterest1Shares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3418941</RGBP:SharesIssuedForInterest1Shares>
    <RGBP:SharesIssuedForInterest1Shares contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1819077</RGBP:SharesIssuedForInterest1Shares>
    <RGBP:SharesIssuedForInterest1Value contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">236</RGBP:SharesIssuedForInterest1Value>
    <RGBP:SharesIssuedForInterest1Value contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">1641</RGBP:SharesIssuedForInterest1Value>
    <RGBP:SharesIssuedForInterest1Value contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">342</RGBP:SharesIssuedForInterest1Value>
    <RGBP:SharesIssuedForInterest1Value contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1299</RGBP:SharesIssuedForInterest1Value>
    <RGBP:SharesIssuedForInterest1Value contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">182</RGBP:SharesIssuedForInterest1Value>
    <RGBP:SharesIssuedForInterest1Value contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">54</RGBP:SharesIssuedForInterest1Value>
    <RGBP:SharesIssuedForDebt2Shares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">25002163</RGBP:SharesIssuedForDebt2Shares>
    <RGBP:SharesIssuedForDebt2Shares contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">60834498</RGBP:SharesIssuedForDebt2Shares>
    <RGBP:SharesIssuedForDebt2Amount contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">7300</RGBP:SharesIssuedForDebt2Amount>
    <RGBP:SharesIssuedForDebt2Amount contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">9000</RGBP:SharesIssuedForDebt2Amount>
    <RGBP:SharesIssuedForDebt2Amount contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2500</RGBP:SharesIssuedForDebt2Amount>
    <RGBP:SharesIssuedForDebt2Amount contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6500</RGBP:SharesIssuedForDebt2Amount>
    <RGBP:SharesIssuedForDebt2Amount contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">6083</RGBP:SharesIssuedForDebt2Amount>
    <RGBP:SharesIssuedForDebt2Amount contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1217</RGBP:SharesIssuedForDebt2Amount>
    <RGBP:SharesIssuedForInterestShares2 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">8745416</RGBP:SharesIssuedForInterestShares2>
    <RGBP:SharesIssuedForInterestShares2 contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">26155352</RGBP:SharesIssuedForInterestShares2>
    <RGBP:SharesIssuedForInterestAmount2 contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">1700</RGBP:SharesIssuedForInterestAmount2>
    <RGBP:SharesIssuedForInterestAmount2 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">2625</RGBP:SharesIssuedForInterestAmount2>
    <RGBP:SharesIssuedForInterestAmount2 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">875</RGBP:SharesIssuedForInterestAmount2>
    <RGBP:SharesIssuedForInterestAmount2 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1750</RGBP:SharesIssuedForInterestAmount2>
    <RGBP:SharesIssuedForInterestAmount2 contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2616</RGBP:SharesIssuedForInterestAmount2>
    <RGBP:SharesIssuedForInterestAmount2 contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-916</RGBP:SharesIssuedForInterestAmount2>
    <RGBP:SharesIssuedForFees1Shares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5548380</RGBP:SharesIssuedForFees1Shares>
    <RGBP:SharesIssuedForFees1Shares contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1228077</RGBP:SharesIssuedForFees1Shares>
    <RGBP:SharesIssuedForFees1Value contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">159</RGBP:SharesIssuedForFees1Value>
    <RGBP:SharesIssuedForFees1Value contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">500</RGBP:SharesIssuedForFees1Value>
    <RGBP:SharesIssuedForFees1Value contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">555</RGBP:SharesIssuedForFees1Value>
    <RGBP:SharesIssuedForFees1Value contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-55</RGBP:SharesIssuedForFees1Value>
    <RGBP:SharesIssuedForFees1Value contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">123</RGBP:SharesIssuedForFees1Value>
    <RGBP:SharesIssuedForFees1Value contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">36</RGBP:SharesIssuedForFees1Value>
    <RGBP:SharesIssuedForDebt3Shares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">19254584</RGBP:SharesIssuedForDebt3Shares>
    <RGBP:SharesIssuedForDebt3Shares contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3300000</RGBP:SharesIssuedForDebt3Shares>
    <RGBP:SharesIssuedForDebt3Amount contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">429</RGBP:SharesIssuedForDebt3Amount>
    <RGBP:SharesIssuedForDebt3Amount contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">5775</RGBP:SharesIssuedForDebt3Amount>
    <RGBP:SharesIssuedForDebt3Amount contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1925</RGBP:SharesIssuedForDebt3Amount>
    <RGBP:SharesIssuedForDebt3Amount contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3850</RGBP:SharesIssuedForDebt3Amount>
    <RGBP:SharesIssuedForDebt3Amount contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">330</RGBP:SharesIssuedForDebt3Amount>
    <RGBP:SharesIssuedForDebt3Amount contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">99</RGBP:SharesIssuedForDebt3Amount>
    <RGBP:SharesIssuedForInterestShares4 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">36500000</RGBP:SharesIssuedForInterestShares4>
    <RGBP:SharesIssuedForInterestShares4 contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">19555555</RGBP:SharesIssuedForInterestShares4>
    <RGBP:SharesIssuedForInterestAmount4 contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">3250</RGBP:SharesIssuedForInterestAmount4>
    <RGBP:SharesIssuedForInterestAmount4 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">6570</RGBP:SharesIssuedForInterestAmount4>
    <RGBP:SharesIssuedForInterestAmount4 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3650</RGBP:SharesIssuedForInterestAmount4>
    <RGBP:SharesIssuedForInterestAmount4 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2920</RGBP:SharesIssuedForInterestAmount4>
    <RGBP:SharesIssuedForInterestAmount4 contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1956</RGBP:SharesIssuedForInterestAmount4>
    <RGBP:SharesIssuedForInterestAmount4 contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1294</RGBP:SharesIssuedForInterestAmount4>
    <RGBP:SharesIssuedForDebt5Shares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">31251177</RGBP:SharesIssuedForDebt5Shares>
    <RGBP:SharesIssuedForDebt5Shares contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">68333539</RGBP:SharesIssuedForDebt5Shares>
    <RGBP:SharesIssuedForDebt5Amount contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">8200</RGBP:SharesIssuedForDebt5Amount>
    <RGBP:SharesIssuedForDebt5Amount contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">6750</RGBP:SharesIssuedForDebt5Amount>
    <RGBP:SharesIssuedForDebt5Amount contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3125</RGBP:SharesIssuedForDebt5Amount>
    <RGBP:SharesIssuedForDebt5Amount contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3625</RGBP:SharesIssuedForDebt5Amount>
    <RGBP:SharesIssuedForDebt5Amount contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">6833</RGBP:SharesIssuedForDebt5Amount>
    <RGBP:SharesIssuedForDebt5Amount contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1367</RGBP:SharesIssuedForDebt5Amount>
    <RGBP:SharesIssuedForInterestShares5 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4393684</RGBP:SharesIssuedForInterestShares5>
    <RGBP:SharesIssuedForInterestShares5 contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">14883378</RGBP:SharesIssuedForInterestShares5>
    <RGBP:SharesIssuedForInterestAmount5 contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">1700</RGBP:SharesIssuedForInterestAmount5>
    <RGBP:SharesIssuedForInterestAmount5 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">949</RGBP:SharesIssuedForInterestAmount5>
    <RGBP:SharesIssuedForInterestAmount5 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">439</RGBP:SharesIssuedForInterestAmount5>
    <RGBP:SharesIssuedForInterestAmount5 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">510</RGBP:SharesIssuedForInterestAmount5>
    <RGBP:SharesIssuedForInterestAmount5 contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1488</RGBP:SharesIssuedForInterestAmount5>
    <RGBP:SharesIssuedForInterestAmount5 contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">212</RGBP:SharesIssuedForInterestAmount5>
    <RGBP:SharesIssuedForDebt6Shares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">30558094</RGBP:SharesIssuedForDebt6Shares>
    <RGBP:SharesIssuedForDebt6Shares contextRef="From2020-10-01to2020-12-31_custom_SeriesAPreferredStocksMember" unitRef="Shares" decimals="INF">20000437</RGBP:SharesIssuedForDebt6Shares>
    <RGBP:SharesIssuedForDebt6Amount contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">13000</RGBP:SharesIssuedForDebt6Amount>
    <RGBP:SharesIssuedForDebt6Amount contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">5500</RGBP:SharesIssuedForDebt6Amount>
    <RGBP:SharesIssuedForDebt6Amount contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3056</RGBP:SharesIssuedForDebt6Amount>
    <RGBP:SharesIssuedForDebt6Amount contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2444</RGBP:SharesIssuedForDebt6Amount>
    <RGBP:SharesIssuedForDebt6Amount contextRef="From2020-10-01to2020-12-31_custom_SeriesAPreferredStocksMember" unitRef="USD" decimals="0">2000</RGBP:SharesIssuedForDebt6Amount>
    <RGBP:SharesIssuedForDebt6Amount contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">11000</RGBP:SharesIssuedForDebt6Amount>
    <RGBP:SharesIssuedForInterestShares6 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5556017</RGBP:SharesIssuedForInterestShares6>
    <RGBP:SharesIssuedForInterestShares6 contextRef="From2020-10-01to2020-12-31_custom_SeriesAPreferredStocksMember" unitRef="Shares" decimals="INF">12378732</RGBP:SharesIssuedForInterestShares6>
    <RGBP:SharesIssuedForInterestAmount6 contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">8046</RGBP:SharesIssuedForInterestAmount6>
    <RGBP:SharesIssuedForInterestAmount6 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">1000</RGBP:SharesIssuedForInterestAmount6>
    <RGBP:SharesIssuedForInterestAmount6 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">556</RGBP:SharesIssuedForInterestAmount6>
    <RGBP:SharesIssuedForInterestAmount6 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">444</RGBP:SharesIssuedForInterestAmount6>
    <RGBP:SharesIssuedForInterestAmount6 contextRef="From2020-10-01to2020-12-31_custom_SeriesAPreferredStocksMember" unitRef="USD" decimals="0">1238</RGBP:SharesIssuedForInterestAmount6>
    <RGBP:SharesIssuedForInterestAmount6 contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6808</RGBP:SharesIssuedForInterestAmount6>
    <RGBP:SharesIssuedForDebt7Shares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">31234276</RGBP:SharesIssuedForDebt7Shares>
    <RGBP:SharesIssuedForDebt7Shares contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">88888889</RGBP:SharesIssuedForDebt7Shares>
    <RGBP:SharesIssuedForDebt7Amount contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">16000</RGBP:SharesIssuedForDebt7Amount>
    <RGBP:SharesIssuedForDebt7Amount contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">6090</RGBP:SharesIssuedForDebt7Amount>
    <RGBP:SharesIssuedForDebt7Amount contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3123</RGBP:SharesIssuedForDebt7Amount>
    <RGBP:SharesIssuedForDebt7Amount contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2967</RGBP:SharesIssuedForDebt7Amount>
    <RGBP:SharesIssuedForDebt7Amount contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">8889</RGBP:SharesIssuedForDebt7Amount>
    <RGBP:SharesIssuedForDebt7Amount contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">7111</RGBP:SharesIssuedForDebt7Amount>
    <RGBP:SharesIssuedForInterestShares1 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5308288</RGBP:SharesIssuedForInterestShares1>
    <RGBP:SharesIssuedForInterestShares1 contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">35832781</RGBP:SharesIssuedForInterestShares1>
    <RGBP:SharesIssuedForInterestAmount contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">2329</RGBP:SharesIssuedForInterestAmount>
    <RGBP:SharesIssuedForInterestAmount contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">1035</RGBP:SharesIssuedForInterestAmount>
    <RGBP:SharesIssuedForInterestAmount contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">531</RGBP:SharesIssuedForInterestAmount>
    <RGBP:SharesIssuedForInterestAmount contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">504</RGBP:SharesIssuedForInterestAmount>
    <RGBP:SharesIssuedForInterestAmount contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3583</RGBP:SharesIssuedForInterestAmount>
    <RGBP:SharesIssuedForInterestAmount contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-1254</RGBP:SharesIssuedForInterestAmount>
    <RGBP:SharesIssuedForDebt8Shares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">41922222</RGBP:SharesIssuedForDebt8Shares>
    <RGBP:SharesIssuedForDebt8Shares contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">82004603</RGBP:SharesIssuedForDebt8Shares>
    <RGBP:SharesIssuedForDebt8Amount contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">5330</RGBP:SharesIssuedForDebt8Amount>
    <RGBP:SharesIssuedForDebt8Amount contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">7546</RGBP:SharesIssuedForDebt8Amount>
    <RGBP:SharesIssuedForDebt8Amount contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4192</RGBP:SharesIssuedForDebt8Amount>
    <RGBP:SharesIssuedForDebt8Amount contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3354</RGBP:SharesIssuedForDebt8Amount>
    <RGBP:SharesIssuedForDebt8Amount contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">8200</RGBP:SharesIssuedForDebt8Amount>
    <RGBP:SharesIssuedForDebt8Amount contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-2870</RGBP:SharesIssuedForDebt8Amount>
    <RGBP:SharesIssuedForDebt9Shares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">10064761</RGBP:SharesIssuedForDebt9Shares>
    <RGBP:SharesIssuedForDebt9Amount contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">907</RGBP:SharesIssuedForDebt9Amount>
    <RGBP:SharesIssuedForDebt9Amount contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1006</RGBP:SharesIssuedForDebt9Amount>
    <RGBP:SharesIssuedForDebt9Amount contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-99</RGBP:SharesIssuedForDebt9Amount>
    <RGBP:SharesIssuedForInterestShares7 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">26310416</RGBP:SharesIssuedForInterestShares7>
    <RGBP:SharesIssuedForInterestAmount7 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">2371</RGBP:SharesIssuedForInterestAmount7>
    <RGBP:SharesIssuedForInterestAmount7 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2631</RGBP:SharesIssuedForInterestAmount7>
    <RGBP:SharesIssuedForInterestAmount7 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-260</RGBP:SharesIssuedForInterestAmount7>
    <RGBP:SharesIssuedForDebt10Shares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">49729272</RGBP:SharesIssuedForDebt10Shares>
    <RGBP:SharesIssuedForDebt10Amount contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">5878</RGBP:SharesIssuedForDebt10Amount>
    <RGBP:SharesIssuedForDebt10Amount contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4973</RGBP:SharesIssuedForDebt10Amount>
    <RGBP:SharesIssuedForDebt10Amount contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">905</RGBP:SharesIssuedForDebt10Amount>
    <RGBP:CommonSharesIssuedForDebtShares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">37777157</RGBP:CommonSharesIssuedForDebtShares>
    <RGBP:CommonSharesIssuedForDebtAmount contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">2266</RGBP:CommonSharesIssuedForDebtAmount>
    <RGBP:CommonSharesIssuedForDebtAmount contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3778</RGBP:CommonSharesIssuedForDebtAmount>
    <RGBP:CommonSharesIssuedForDebtAmount contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-1512</RGBP:CommonSharesIssuedForDebtAmount>
    <RGBP:SharesIssuedForFeesShares3 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">8335648</RGBP:SharesIssuedForFeesShares3>
    <RGBP:SharesIssuedForFeesAmount3 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">500</RGBP:SharesIssuedForFeesAmount3>
    <RGBP:SharesIssuedForFeesAmount3 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">834</RGBP:SharesIssuedForFeesAmount3>
    <RGBP:SharesIssuedForFeesAmount3 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-334</RGBP:SharesIssuedForFeesAmount3>
    <RGBP:SharesIssuedForDebtShares11 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">52200000</RGBP:SharesIssuedForDebtShares11>
    <RGBP:SharesIssuedForDebtAmount11 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">3132</RGBP:SharesIssuedForDebtAmount11>
    <RGBP:SharesIssuedForDebtAmount11 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5220</RGBP:SharesIssuedForDebtAmount11>
    <RGBP:SharesIssuedForDebtAmount11 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-2088</RGBP:SharesIssuedForDebtAmount11>
    <RGBP:SharesIssuedForDebtShares12 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">42081411</RGBP:SharesIssuedForDebtShares12>
    <RGBP:SharesIssuedForDebtAmount12 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">5470</RGBP:SharesIssuedForDebtAmount12>
    <RGBP:SharesIssuedForDebtAmount12 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4208</RGBP:SharesIssuedForDebtAmount12>
    <RGBP:SharesIssuedForDebtAmount12 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1262</RGBP:SharesIssuedForDebtAmount12>
    <RGBP:SharesIssuedForInterestShares8 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">7677742</RGBP:SharesIssuedForInterestShares8>
    <RGBP:SharesIssuedForInterestAmount8 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">998</RGBP:SharesIssuedForInterestAmount8>
    <RGBP:SharesIssuedForInterestAmount8 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">768</RGBP:SharesIssuedForInterestAmount8>
    <RGBP:SharesIssuedForInterestAmount8 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">230</RGBP:SharesIssuedForInterestAmount8>
    <RGBP:SharesIssuedForDebtShares13 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">41433258</RGBP:SharesIssuedForDebtShares13>
    <RGBP:SharesIssuedForDebtAmount13 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">7457</RGBP:SharesIssuedForDebtAmount13>
    <RGBP:SharesIssuedForDebtAmount13 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4143</RGBP:SharesIssuedForDebtAmount13>
    <RGBP:SharesIssuedForDebtAmount13 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3314</RGBP:SharesIssuedForDebtAmount13>
    <RGBP:SharesIssuedForInterestShares9 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">566742</RGBP:SharesIssuedForInterestShares9>
    <RGBP:SharesIssuedForInterestAmount9 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">102</RGBP:SharesIssuedForInterestAmount9>
    <RGBP:SharesIssuedForInterestAmount9 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">57</RGBP:SharesIssuedForInterestAmount9>
    <RGBP:SharesIssuedForInterestAmount9 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">45</RGBP:SharesIssuedForInterestAmount9>
    <RGBP:SharesIssuedForDebtShares14 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">50462834</RGBP:SharesIssuedForDebtShares14>
    <RGBP:SharesIssuedForDebtAmount14 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">3280</RGBP:SharesIssuedForDebtAmount14>
    <RGBP:SharesIssuedForDebtAmount14 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5046</RGBP:SharesIssuedForDebtAmount14>
    <RGBP:SharesIssuedForDebtAmount14 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-1766</RGBP:SharesIssuedForDebtAmount14>
    <RGBP:SharesIssuedForInterestShares10 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">9477166</RGBP:SharesIssuedForInterestShares10>
    <RGBP:SharesIssuedForInterestAmount10 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">616</RGBP:SharesIssuedForInterestAmount10>
    <RGBP:SharesIssuedForInterestAmount10 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">948</RGBP:SharesIssuedForInterestAmount10>
    <RGBP:SharesIssuedForInterestAmount10 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-332</RGBP:SharesIssuedForInterestAmount10>
    <RGBP:SharesIssuedForDebtShares15 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">59900000</RGBP:SharesIssuedForDebtShares15>
    <RGBP:SharesIssuedForDebtAmount15 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">3594</RGBP:SharesIssuedForDebtAmount15>
    <RGBP:SharesIssuedForDebtAmount15 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5990</RGBP:SharesIssuedForDebtAmount15>
    <RGBP:SharesIssuedForDebtAmount15 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-2396</RGBP:SharesIssuedForDebtAmount15>
    <RGBP:SharesIssuedForDebtShares16 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">31421505</RGBP:SharesIssuedForDebtShares16>
    <RGBP:SharesIssuedForDebtAmount16 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">942</RGBP:SharesIssuedForDebtAmount16>
    <RGBP:SharesIssuedForDebtAmount16 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3142</RGBP:SharesIssuedForDebtAmount16>
    <RGBP:SharesIssuedForDebtAmount16 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-2200</RGBP:SharesIssuedForDebtAmount16>
    <RGBP:SharesIssuedForInterestShares11 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">11808081</RGBP:SharesIssuedForInterestShares11>
    <RGBP:SharesIssuedForInterestAmount11 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">354</RGBP:SharesIssuedForInterestAmount11>
    <RGBP:SharesIssuedForInterestAmount11 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1181</RGBP:SharesIssuedForInterestAmount11>
    <RGBP:SharesIssuedForInterestAmount11 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-827</RGBP:SharesIssuedForInterestAmount11>
    <RGBP:SharesIssuedForFeesShares4 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">16678081</RGBP:SharesIssuedForFeesShares4>
    <RGBP:SharesIssuedForFeesAmount4 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">500</RGBP:SharesIssuedForFeesAmount4>
    <RGBP:SharesIssuedForFeesAmount4 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1668</RGBP:SharesIssuedForFeesAmount4>
    <RGBP:SharesIssuedForFeesAmount4 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-1168</RGBP:SharesIssuedForFeesAmount4>
    <RGBP:SharesIssuedForInterestShares12 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">6101694</RGBP:SharesIssuedForInterestShares12>
    <RGBP:SharesIssuedForInterestAmount12 contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">366</RGBP:SharesIssuedForInterestAmount12>
    <RGBP:SharesIssuedForInterestAmount12 contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">610</RGBP:SharesIssuedForInterestAmount12>
    <RGBP:SharesIssuedForInterestAmount12 contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-244</RGBP:SharesIssuedForInterestAmount12>
    <RGBP:CapitalContribution contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">1865</RGBP:CapitalContribution>
    <RGBP:CapitalContribution contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">133</RGBP:CapitalContribution>
    <RGBP:CapitalContribution contextRef="From2019-10-01to2019-12-31_custom_ContributedCapitalMember" unitRef="USD" decimals="0">133</RGBP:CapitalContribution>
    <RGBP:CapitalContribution contextRef="From2020-10-01to2020-12-31_custom_ContributedCapitalMember" unitRef="USD" decimals="0">1865</RGBP:CapitalContribution>
    <us-gaap:ProfitLoss contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">1666367</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">3083375</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">3082768</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">1666367</us-gaap:ProfitLoss>
    <RGBP:SharesIssuedForDebt4Amount contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">4030</RGBP:SharesIssuedForDebt4Amount>
    <RGBP:SharesIssuedForDebt4Amount contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">6200</RGBP:SharesIssuedForDebt4Amount>
    <RGBP:SharesIssuedForDebt4Amount contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-2170</RGBP:SharesIssuedForDebt4Amount>
    <RGBP:SharesIssuedForDebt4Shares contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">62003571</RGBP:SharesIssuedForDebt4Shares>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;NOTE 1. ORGANIZATION AND SUMMARY&#13;OF SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company was organized April&#13;24, 2012 under the laws of the State of Nevada&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company intends to engage&#13;primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful&#13;completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications&#13;or, alternatively, advance the application further to Phase III clinical trials.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company is currently engaged&#13;in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and&#13;immune cell suppression for autoimmune disease.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company is in the early&#13;stages of development of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to&#13;market any of The Company&amp;#8217;s products or therapies. No approval has been granted by the FDA for the marketing and sale of any of&#13;the Company&amp;#8217;s products and therapies and no assurance may be given that any of the Company&amp;#8217;s products or therapies will be&#13;granted such approval. The Company&amp;#8217;s current plans include the development of regenerative medical applications up to the point&#13;of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to sell or license those&#13;developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company can provide no assurance&#13;that the Company will be able to sell or license any product or that, if such product is sold or licensed, such sale or license will be&#13;on terms favorable to the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;A. BASIS OF ACCOUNTING&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The financial statements have&#13;been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues&#13;are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;B. PRINCIPLES OF CONSOLIDATION&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The consolidated financial statements include&#13;the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions&#13;have been eliminated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;br /&gt;&#13;The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives&#13;and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained&#13;in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change&#13;in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying&#13;amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model.&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Black Scholes pricing model used to determine&#13;the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of December 31, 2020&#13;utilized the following inputs:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Risk Free Interest Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected Term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;.34&amp;#8211; -1.87 Yrs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;743%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected Dividends&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;H. INCOME TAXES&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company accounts for income&#13;taxes using the liability method prescribed by ASC 740, &amp;#8220;Income Taxes.&amp;#8221; Under this method, deferred tax assets and liabilities&#13;are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates&#13;that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset&#13;deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred&#13;tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that&#13;includes the enactment date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company applied the provisions&#13;of ASC 740-10-50, &amp;#8220;Accounting For Uncertainty In Income Taxes&amp;#8221;, which provides clarification related to the process associated&#13;with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute&#13;of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result&#13;in an adjustment to the Company&amp;#8217;s liability for income taxes. Any such adjustment could be material to the Company&amp;#8217;s results&#13;of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of December&#13;31, 2020 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company generated a deferred&#13;tax credit through net operating loss carry forward. &amp;#160;However, a valuation allowance of 100% has been established.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Interest and penalties on tax&#13;deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;I. &amp;#160;BASIC EARNINGS (LOSS)&#13;PER SHARE&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Financial Accounting Standards&#13;Board (FASB) issued Accounting Standards Codification (ASC) 260, &amp;#8220;Earnings Per Share&amp;#8221;, which specifies the computation, presentation&#13;and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation&#13;of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective&#13;from inception.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Basic net loss per share amounts&#13;is computed by dividing the net income by the weighted average number of common shares outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;J. ADVERTISING&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Costs associated with advertising&#13;are charged to expense as incurred. Advertising expenses were $0 for the quarters ended December 31 2020 and December 31, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;K. NOTES RECEIVABLE&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Notes receivable are stated&#13;at cost, less impairment, if any.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;L. REVENUE RECOGNITION&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Sales of products and related&#13;costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price&#13;is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing&#13;and shipment of products.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company determines the amount&#13;and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty&#13;revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties&#13;are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage&#13;to the Company&amp;#8217;s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee&amp;#8217;s&#13;sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon&#13;satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;M. INTEREST RECEIVABLE&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Interest receivable is stated&#13;at cost, less impairment, if any.&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;NOTE 2.&amp;#160;&amp;#160;RECENT ACCOUNTING&#13;PRONOUNCEMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In June 2014, the Financial&#13;Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of&#13;companies previously identified as &amp;#8220;Development Stage Entities&amp;#8221; (Topic 915). The amendments in this ASU simplify accounting&#13;guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data&#13;maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present&#13;inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments&#13;is permitted for any annual reporting period or interim period for which the entity&amp;#8217;s financial statements have not yet been issued&#13;(public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose&#13;any information required by Topic 915. The Company has adopted this standard.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;As of the fiscal year ending&#13;September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The&#13;guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific&#13;guidance throughout the Industry Topics of the Codification.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The core principle of the guidance&#13;is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects&#13;the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle,&#13;an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations&#13;in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the&#13;contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In June 2014, FASB issued Accounting&#13;Standards Update (ASU) No. 2014-12 Compensation &amp;#8212; Stock Compensation (Topic 718), Accounting for Share-Based Payments When the&#13;Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based&#13;payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition&#13;under Accounting Standards Codification (ASC) 718, Compensation &amp;#8212; Stock Compensation. As a result, the target is not reflected&#13;in the estimation of the award&amp;#8217;s grant date fair value. Compensation cost would be recognized over the required service period,&#13;if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December&#13;2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has&#13;not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on&#13;the consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In August 2014, FASB issued&#13;Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements &amp;#8211; Going Concern (Subtopic 205-40), Disclosure&#13;of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP),&#13;continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the&#13;entity&amp;#8217;s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the&#13;going concern basis of accounting. If and when an entity&amp;#8217;s liquidation becomes imminent, financial statements should be prepared&#13;under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements&amp;#8212;Liquidation Basis&#13;of Accounting. Even when an entity&amp;#8217;s liquidation is not imminent, there may be conditions or events that raise substantial doubt&#13;about the entity&amp;#8217;s ability to continue as a going concern. In those situations, financial statements should continue to be prepared&#13;under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information&#13;about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15,&#13;2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern&#13;considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject&#13;these financial statements for additional disclosure.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On January 31, 2013, the FASB&#13;issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities.&#13;The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance&#13;Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify&amp;#160;that ordinary trade receivables and receivables in general are not within&#13;the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC&#13;210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now&#13;clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse&#13;repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements,&#13;or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods&#13;beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have&#13;a material impact on our financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On February 28, 2013, the FASB&#13;issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which&#13;the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards&#13;Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint&#13;and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The amount the reporting entity&#13;agreed to pay on the basis of its arrangement among co-obligors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Any additional amounts the reporting&#13;entity expects to pay on behalf of its co-obligors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;While early adoption of the&#13;amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within&#13;those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for&#13;obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption&#13;of ASU 2013-04 is not expected to have a material effect on the Company&amp;#8217;s operating results or financial position.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On April 22, 2013, the FASB issued Accounting&#13;Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB&#13;Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify&#13;when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities,&#13;whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of&#13;assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07&#13;are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods.&#13;Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent.&#13;Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company&amp;#8217;s operating results&#13;or financial position.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In January 2016, the Financial Accounting Standards&#13;Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification&#13;and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial&#13;liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the&#13;ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses&#13;on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15,&#13;2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the&#13;beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to&#13;record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other&#13;comprehensive income. The Company adopted ASU 2016-01 as of the fiscal year ending September 30, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;A variety of proposed or otherwise potential&#13;accounting standards are currently under study by standard setting organizations and various regulatory agencies.&amp;#160;&amp;#160;Due to the&#13;tentative and preliminary nature of those proposed standards, the Company&amp;#8217;s management has not determined whether implementation&#13;of such standards would be material to its financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;NOTE 3. GOING CONCERN&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The accompanying financial statements have&#13;been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $14,917,300 during the period&#13;from April 24, 2012 (inception) through December 31, 2020. This condition raises substantial doubt about the Company&amp;#8217;s ability to&#13;continue as a going concern. The Company&amp;#8217;s continuation as a going concern is dependent on its ability to meet its obligations,&#13;to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any&#13;adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Management plans to raise additional funds&#13;by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company&#13;will raise.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;NOTE 4. NOTES PAYABLE, RELATED PARTY&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;As of December 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 71%"&gt;&lt;font style="font-size: 10pt"&gt;David Koos&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;227&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;BST Partners&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;61,900&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Total:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;$227 lent to the Company by David Koos is due&#13;and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 2, 2019 BST Partners, an entity&#13;controlled by the Company&amp;#8217;s CEO loaned $6,000 to the Company. The loan bears simple interest at 10% and is due and payable October&#13;2, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 4, 2019 BST Partners, an entity&#13;controlled by the Company&amp;#8217;s CEO loaned $2,300 to the Company. The loan bears simple interest at 10% and is due and payable October&#13;4, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 24, 2019 BST Partners, an entity&#13;controlled by the Company&amp;#8217;s CEO loaned $7,400 to the Company. The loan bears simple interest at 10% and is due and payable October&#13;24, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 25, 2019 BST Partners, an entity&#13;controlled by the Company&amp;#8217;s CEO loaned $1,000 to the Company. The loan bears simple interest at 10% and is due and payable October&#13;25, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 31, 2019 BST Partners, an entity&#13;controlled by the Company&amp;#8217;s CEO loaned $2,000 to the Company. The loan bears simple interest at 10% and is due and payable October&#13;31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On November 6, 2019 BST Partners, an entity&#13;controlled by the Company&amp;#8217;s CEO loaned $1,500 to the Company. The loan bears simple interest at 10% and is due and payable November&#13;6, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On November 8, 2019 BST Partners, an entity&#13;controlled by the Company&amp;#8217;s CEO loaned $6,000 to the Company. The loan bears simple interest at 10% and is due and payable November&#13;8, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On November 15, 2019 BST Partners, an entity&#13;controlled by the Company&amp;#8217;s CEO loaned $2,000 to the Company. The loan bears simple interest at 10% and is due and payable November&#13;15, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On November 26, 2019 BST Partners, an entity&#13;controlled by the Company&amp;#8217;s CEO loaned $2,100 to the Company. The loan bears simple interest at 10% and is due and payable November&#13;26, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 2, 2019 BST Partners, an entity&#13;controlled by the Company&amp;#8217;s CEO loaned $1,000 to the Company. The loan bears simple interest at 10% and is due and payable December&#13;2, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 17, 2019 BST Partners, an entity&#13;controlled by the Company&amp;#8217;s CEO loaned $1,300 to the Company. The loan bears simple interest at 10% and is due and payable December&#13;18, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On January 2, 2020 BST Partners, an entity&#13;controlled by the Company&amp;#8217;s CEO loaned $1,400 to the Company. The loan bears simple interest at 10% and is due and payable January&#13;2, 2021.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On January 10, 2020 BST Partners, an entity&#13;controlled by the Company&amp;#8217;s CEO loaned $2,500 to the Company. The loan bears simple interest at 10% and is due and payable January&#13;10, 2021&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On January 16, 2020 BST Partners, an entity&#13;controlled by the Company&amp;#8217;s CEO loaned $1,400 to the Company. The loan bears simple interest at 10% and is due and payable January&#13;16, 2021&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;During the year ended September 30, 2020 David&#13;Koos served as the Company&amp;#8217;s Chairman and CEO until January 22, 2020. On March 23, 2021 David R. Koos was appointed Chairman and&#13;Sole Director of Regen Biopharma, Inc. On March 23, 2021 David R. Koos was appointed Chief Executive Officer, President, Secretary and&#13;Treasurer of Regen Biopharma, Inc. On March 23, 2021 David R. Koos was appointed Chairman and Sole Director of KCL Therapeutics, Inc.&#13;On March 23, 2021 David R. Koos was appointed Chief Executive Officer, President, Secretary and Treasurer of KCL Therapeutics, Inc.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <RGBP:ConvertibleNotesPayableTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;NOTE 5. CONVERTIBLE NOTES PAYABLE&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On March 8, 2016 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $100,000 for consideration consisting of&#13;$100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Lender shall have the right&#13;from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable&#13;shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company&#13;into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;(a) For the period beginning&#13;on the Issue Date and ending 365 days subsequent to the Issue Date (&amp;#8220;Year 1&amp;#8221;) a 50% discount to the lowest Trading Price (as&#13;defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day&#13;prior to the Conversion Date or ten cents per share (whichever is greater).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;(b) For the period beginning&#13;one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (&amp;#8220;Year 2&amp;#8221;) a 35% discount to the&#13;lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest&#13;complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;(c) For the period beginning&#13;one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (&amp;#8220;Year 3&amp;#8221;) a 25% discount to the lowest&#13;Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete&#13;Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;(d) &amp;#8220;Trading Price&amp;#8221;&#13;means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the &amp;#8220;OTCQB&amp;#8221;) as reported&#13;by a reliable reporting service (&amp;#8220;Reporting Service&amp;#8221;) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the&#13;principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market&#13;where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the&#13;average of the closing bid prices of any market makers for such security that are listed in the &amp;#8220;pink sheets&amp;#8221; by the National&#13;Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading&#13;Price shall be the fair market value as mutually determined by the Company and the Lender. &amp;#8220;Trading Day&amp;#8221; shall mean any day&#13;on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market&#13;on which the Common Stock is then being traded. &amp;#8220;Trading Volume&amp;#8221; shall mean the number of shares traded on such Trading Day&#13;as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings,&#13;combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender&amp;#8217;s&#13;securities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company shall have the right,&#13;exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full,&#13;including outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Upon closing of a Transaction&#13;Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated&#13;third party as a result of the closing of a Transaction Event.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&amp;#8220;Transaction Event&amp;#8221;&#13;shall mean either of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;(a) The sale by the Company&#13;of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;(b) The granting of a license&#13;by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company&amp;#8217;s&#13;proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The issuance of the Note amounted&#13;in a beneficial conversion feature of $42,600 which is amortized under the Interest Method over the life of the Note. As of December 31,&#13;2020 the unamortized discount on the convertible note outstanding is $ 0. As of December 31, 2020 $100,000 of the principal amount of&#13;the Note remains outstanding.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On April 6, 2016 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of&#13;$50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Lender shall have the right&#13;from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable&#13;shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company&#13;into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;(a) For the period beginning&#13;on the Issue Date and ending 365 days subsequent to the Issue Date (&amp;#8220;Year 1&amp;#8221;) a 50% discount to the lowest Trading Price (as&#13;defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day&#13;prior to the Conversion Date or ten cents per share (whichever is greater).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;(b) For the period beginning&#13;one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (&amp;#8220;Year 2&amp;#8221;) a 35% discount to the&#13;lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest&#13;complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;(c) For the period beginning&#13;one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (&amp;#8220;Year 3&amp;#8221;) a 25% discount to the lowest&#13;Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete&#13;Trading Day prior to the Conversion Date or ten cents per share (whichever is greater).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;(d) &amp;#8220;Trading Price&amp;#8221;&#13;means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the &amp;#8220;OTCQB&amp;#8221;) as reported&#13;by a reliable reporting service (&amp;#8220;Reporting Service&amp;#8221;) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the&#13;principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market&#13;where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the&#13;average of the closing bid prices of any market makers for such security that are listed in the &amp;#8220;pink sheets&amp;#8221; by the National&#13;Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading&#13;Price shall be the fair market value as mutually determined by the Company and the Lender. &amp;#8220;Trading Day&amp;#8221; shall mean any day&#13;on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market&#13;on which the Common Stock is then being traded. &amp;#8220;Trading Volume&amp;#8221; shall mean the number of shares traded on such Trading Day&#13;as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings,&#13;combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender&amp;#8217;s&#13;securities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company shall have the right,&#13;exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full,&#13;including outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Upon closing of a Transaction&#13;Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated&#13;third party as a result of the closing of a Transaction Event.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&amp;#8220;Transaction Event&amp;#8221;&#13;shall mean either of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;(a) The sale by the Company&#13;of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;(b) The granting of a license&#13;by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company&amp;#8217;s&#13;proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The issuance of the Note amounted&#13;in a beneficial conversion feature of $9,900 which is amortized under the Interest Method over the life of the Note. As of December 31,&#13;2019 the unamortized discount on the convertible note outstanding is $0. As of December 31, 2020 $50,000 of the principal amount of the&#13;Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On September 8, 2016 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of&#13;$50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Lender shall have the right&#13;from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable&#13;shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other&#13;securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company shall have the right,&#13;exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full,&#13;including outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The issuance of the Note amounted&#13;in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,&#13;2020 the unamortized discount on the convertible note outstanding is $ 0. As of December 31, 2020 $50,000 of the principal amount of the&#13;Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On September 20, 2016 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of&#13;$50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Lender shall have the right&#13;from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable&#13;shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other&#13;securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company shall have the right,&#13;exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full,&#13;including outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The issuance of the Note amounted&#13;in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,&#13;2020 the unamortized discount on the convertible note outstanding is $ 0. As of December 31, 2020 $50,000 of the principal amount of the&#13;Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On October 31, 2016 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of&#13;$50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Lender shall have the right&#13;from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable&#13;shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other&#13;securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company shall have the right,&#13;exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full,&#13;including outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The issuance of the Note amounted&#13;in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,&#13;2020 the unamortized discount on the convertible note outstanding is $0. As of December 31, 2020 $50,000 of the principal amount of the&#13;Note remains outstanding.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On October 31, 2016 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of&#13;$50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Lender shall have the right&#13;from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable&#13;shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other&#13;securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company shall have the right,&#13;exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full,&#13;including outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The issuance of the Note amounted&#13;in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,&#13;2020 the unamortized discount on the convertible note outstanding is $ 0 As of December 31, 2020 $50,000 of the principal amount of the&#13;Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On October 31, 2016 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of&#13;$50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Lender shall have the right&#13;from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable&#13;shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other&#13;securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company shall have the right,&#13;exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full,&#13;including outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The issuance of the Note amounted&#13;in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,&#13;2020 the unamortized discount on the convertible note outstanding is $0. As of December 31, 2020 $50,000 of the principal amount of the&#13;Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On December 22, 2016 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $40,000 for consideration consisting of&#13;$40,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Lender shall have the right&#13;from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable&#13;shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other&#13;securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.01 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company shall have the right,&#13;exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full,&#13;including outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The issuance of the Note amounted&#13;in a beneficial conversion feature of $40,000 which is amortized under the Interest Method over the life of the Note. As of December 31,&#13;2020 the unamortized discount on the convertible note outstanding is $ 0. As of December 31, 2020 $40,000 of the principal amount of the&#13;Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On March 1, 2017 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $75,000 for consideration consisting of&#13;$75,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 1, 2020. All or part of&#13;the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion&#13;Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day&#13;immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company shall have the right,&#13;exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full,&#13;including outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event that that the Company&#13;exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of&#13;the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining&#13;amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event that the Company&#13;exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note&#13;shall have been prepaid by the Company(&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event , part of the outstanding&#13;and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the&#13;close of business on the three (3) month anniversary of the Maturity Date of the Note. As of December 31 , 2020 $75,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company analyzed the conversion&#13;feature of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that&#13;the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be&#13;delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately&#13;accounted for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance&#13;sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the&#13;income statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company values the embedded&#13;derivative using the Black-Scholes pricing model and a derivative liability of $30,000 was recognized by the Company as of December 31,&#13;2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The issuance of the Note amounted&#13;in a discount of $75,000 which is amortized under the Interest Method over the life of the Note. As of December 31, 2020 the unamortized&#13;discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On March 9, 2017 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $25,000 for consideration consisting of&#13;$25,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 9, 2020. All or part of&#13;the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion&#13;Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day&#13;immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company shall have the right,&#13;exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full,&#13;including outstanding principal and accrued interest..&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event that that the Company&#13;exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of&#13;the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining&#13;amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event that the Company&#13;exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note&#13;shall have been prepaid by the Company(&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event , part of the outstanding&#13;and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the&#13;close of business on the three (3) month anniversary of the Maturity Date of the Note. As of December 31, 2020 $25,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company analyzed the conversion&#13;feature of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that&#13;the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be&#13;delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately&#13;accounted for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance&#13;sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the&#13;income statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company values the embedded&#13;derivative using the Black-Scholes pricing model and a derivative liability of $10,000 was recognized by the Company as of December 31,&#13;2020. The issuance of the Note amounted in a discount of $25,000 which is amortized under the Interest Method over the life of the Note.&#13;As of December 31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;March 13, 2017 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of&#13;$50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is February 24, 2020. All or part&#13;of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion&#13;Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day&#13;immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company shall have the right,&#13;exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full,&#13;including outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event that that the Company&#13;exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of&#13;the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining&#13;amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event that the Company&#13;exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note&#13;shall have been prepaid by the Company(&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event , part of the outstanding&#13;and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the&#13;close of business on the three (3) month anniversary of the Maturity Date of the Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;As of December 31, 2020 $50,000&#13;of the principal amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company analyzed the conversion&#13;feature of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that&#13;the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be&#13;delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately&#13;accounted for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance&#13;sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the&#13;income statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company values the embedded&#13;derivative using the Black-Scholes pricing model and a derivative liability of $20,000 was recognized by the Company as of December 31,&#13;2020. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note.&#13;As of December 31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On March 31, 2017 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of&#13;$50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 31, 2020. All or part of&#13;the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion&#13;Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day&#13;immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company shall have the right,&#13;exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full,&#13;including outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event that that the Company&#13;exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of&#13;the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining&#13;amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event that the Company&#13;exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note&#13;shall have been prepaid by the Company(&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event part of the outstanding&#13;and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the&#13;close of business on the three (3) month anniversary of the Maturity Date of the Note. As of December 31, 2020 $50,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company analyzed the conversion&#13;feature of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that&#13;the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be&#13;delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately&#13;accounted for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance&#13;sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the&#13;income statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company values the embedded&#13;derivative using the Black-Scholes pricing model and a derivative liability of $20,000 was recognized by the Company as of December 31,&#13;2020. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note.&#13;As of December 31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On April 19, 2017 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $25,000 for consideration consisting of&#13;$25,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is April 19, 2020. All or part of&#13;the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion&#13;Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day&#13;immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company shall have the right,&#13;exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full,&#13;including outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event that that the Company&#13;exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of&#13;the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining&#13;amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event that the Company&#13;exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note&#13;shall have been prepaid by the Company(&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event , part of the outstanding&#13;and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the&#13;close of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;As of December 31, 2020 $25,000&#13;of the principal amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company analyzed the conversion&#13;feature of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that&#13;the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be&#13;delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately&#13;accounted for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance&#13;sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the&#13;income statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company values the embedded&#13;derivative using the Black-Scholes pricing model and a derivative liability of $10,000 was recognized by the Company as of December 31,&#13;2020. The issuance of the Note amounted in a discount of $25,000 which is amortized under the Interest Method over the life of the Note.&#13;As of December 31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;&amp;#160;On April 19, 2017 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of&#13;$50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is April 19, 2020. All or part of&#13;the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion&#13;Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day&#13;immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company shall have the right,&#13;exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full,&#13;including outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event that that the Company&#13;exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of&#13;the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining&#13;amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event that the Company&#13;exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note&#13;shall have been prepaid by the Company(&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;In the event , part of the outstanding&#13;and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the&#13;close of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;As of December 31, 2020 $50,000&#13;of the principal amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company analyzed the conversion&#13;feature of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that&#13;the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be&#13;delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately&#13;accounted for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance&#13;sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the&#13;income statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company values the embedded&#13;derivative using the Black-Scholes pricing model and a derivative liability of $10,000 was recognized by the Company as of December 31,&#13;2020. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note.&#13;As of December 31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On May 5, 2017 (&amp;#8220;Issue&#13;date&amp;#8221;) the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $200,000 for consideration consisting of&#13;$200,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is May 5, 2020. The Note is convertible&#13;into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to&#13;the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by&#13;the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company. For purposes of this&#13;Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all&#13;of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members&#13;of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the&#13;Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iii)&amp;#160;That date which is twenty four (24)&#13;months subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company(&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $200,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $$80,000was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $200,000 which is amortized under the Interest Method over the life of the Note. As of&#13;December 31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On May 10, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $100,000 for consideration consisting of $100,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is May 9, 2020. The Note may be converted into&#13;the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to the&#13;closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the&#13;Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company. For purposes of this&#13;Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all&#13;of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members&#13;of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the&#13;Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iii) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company(&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $100,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $40,000 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $100,000 which is amortized under the Interest Method over the life of the Note. As of&#13;December 31,, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On May 19, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of $50,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is May 19, 2020. The Note may be converted into&#13;the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to the&#13;closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the&#13;Lender to Regen or (b) $0.0125 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.0125 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company(&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $50,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $20,000 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December&#13;31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On June 26, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $150,000 for consideration consisting of $150,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is June 16, 2020. The Note may be converted into&#13;the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to the&#13;closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the&#13;Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company(&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $150,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $60,000 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $150,000 which is amortized under the Interest Method over the life of the Note. As of&#13;December 31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On July 24, 2017 the Company issued a Convertible&#13;Note (&amp;#8220;Note&amp;#8221;) in the face amount of $60,000 for consideration consisting of $60,000 cash. The Note bears simple interest at&#13;the rate of 10% per annum and is convertible into the Common Stock of the Company at a price per share equal to the lower of 75% of the&#13;lowest trade price of the date immediately prior to conversion or 0.025 per share. The Note matures July 24, 2020. The Company shall have&#13;the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part&#13;or in full, including outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $60,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;br /&gt;&#13;&lt;br /&gt;&#13;&amp;#160;The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $24,000 was recognized&#13;by the Company as of December 31, 2020. The issuance of the Note amounted in a discount of $60,000 which is amortized under the Interest&#13;Method over the life of the Note. As of December 31 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On August 29, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $25,000 for consideration consisting of $25,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is August 29, 2020. The Note may be converted into&#13;the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to the&#13;closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the&#13;Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company(&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $25,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $10,000 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $25,000 which is amortized under the Interest Method over the life of the Note. As of &amp;#160;December&#13;31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On September 22, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of $50,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is September 21, 2020. The Note may be converted&#13;into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to&#13;the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by&#13;the Lender to Regen or (b) $0.0125 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company (&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $50,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $20,000 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December&#13;31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&amp;#160;On September 22, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $100,000 for consideration consisting of $100,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is September 22, 2020. The Note may be converted&#13;into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to&#13;the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by&#13;the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Com&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company(&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $100,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $40,000 was recognized by the Company as of December 31,2020. The&#13;issuance of the Note amounted in a discount of $100,000 which is amortized under the Interest Method over the life of the Note. As of&#13;December 31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On September 25, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of $50,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is September 25, 2020. The Note may be converted&#13;into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to&#13;the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by&#13;the Lender to Regen or (b) $0.0125 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company (&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $50,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $20,000 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December&#13;31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 3, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of $50,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 3, 2020. The Note may be converted into&#13;the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to the&#13;closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the&#13;Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii) One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company (&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020, $50,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $66,667 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December&#13;31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 4, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $40,000 for consideration consisting of $40,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 4, 2020. The Note may be converted into&#13;the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to the&#13;closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the&#13;Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company (&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $40,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $16,000 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $40,000 which is amortized under the Interest Method over the life of the Note. As of December&#13;31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 16, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $100,000 for consideration consisting of $100,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 9, 2020. The Note may be converted into&#13;the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to the&#13;closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the&#13;Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company (&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $100,000 of the principal&#13;amount of the Note remains outstanding.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $40,000 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $100,000 which is amortized under the Interest Method over the life of the Note. As of&#13;December 31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On November 1, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $25,000 for consideration consisting of $25,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is November 1, 2020. The Note may be converted&#13;into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to&#13;the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by&#13;the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii) One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"&gt;The Company shall have the right, exercisable on not less than ten&#13;(10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal&#13;and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company (&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $25,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $10,000 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $25,000 which is amortized under the Interest Method over the life of the Note. As of December&#13;31 , 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On November 1, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $25,000 for consideration consisting of $25,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is November 1, 2020. The Note may be converted&#13;into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to&#13;the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by&#13;the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii) One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company (&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $25,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $10,000 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $25,000 which is amortized under the Interest Method over the life of the Note. As of December&#13;31 , 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 15, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $35,000 for consideration consisting of $35,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is December 15, 2020. The Note may be converted&#13;into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to&#13;the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by&#13;the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company (&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $35,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $14,000 was recognized by the Company as of &amp;#160;December 31, 2020.&#13;The issuance of the Note amounted in a discount of $35,000 which is amortized under the Interest Method over the life of the Note. As&#13;of December 31, 2020 the unamortized discount on the convertible note outstanding is $383.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 20, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $100,000 for consideration consisting of $100,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is December 20, 2020. The Note may be converted&#13;into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to&#13;the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by&#13;the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i) One day subsequent to the execution of&#13;an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics. For&#13;purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially&#13;all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members&#13;of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the&#13;Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company (&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $100,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $40,000 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $100,000 which is amortized under the Interest Method over the life of the Note. As of&#13;December 31, 2020 the unamortized discount on the convertible note outstanding is $1,551.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 20, 2017 the Company issued a Convertible&#13;Note (&amp;#8220;Note&amp;#8221;) in the face amount of $115,000 for consideration consisting of $100,000 cash and payment on behalf of the Company&#13;of 13,250 of expenses incurred in connection with the issuance of the Note. The Note also carries an Original Issue Discount of $1,750.The&#13;Note pays simple interest in the amount of 8% per annum. The maturity of the Note is December 6, 2018. The Note may be converted into&#13;the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to 65% of the lowest Trading Price of the&#13;Common Stock of the Company as reported on the National Quotations Bureau OTC Markets exchange upon which the Company's shares are traded&#13;or any exchange upon which the Common Stock of the Company may be traded in the future , for the fourteen prior trading days including&#13;the day upon which a Notice of Conversion is received by the Company or its transfer agent. In no event shall the Holder be allowed to&#13;effect a conversion if such conversion, along with all other shares of Company Common Stock beneficially owned by the Holder and its affiliates&#13;would exceed 9.9% of the outstanding shares of the Common Stock of the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Note may be prepaid with the following&#13;penalties:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 47%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Time Period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 43%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Payment Premium&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#60;=60 days after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;115% of the sum of principal&amp;#160;&amp;#160;plus accrued interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#62;60 days &amp;#60;= 120 days after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;125% of the sum of principal&amp;#160;&amp;#160;plus accrued interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#62;120 days &amp;#60;=180 days&amp;#160;&amp;#160;after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;135% of the sum&amp;#183; of principal plus accrued&amp;#183; interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;This Note may not be prepaid after the 180th&amp;#160;day.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $31,893 of the Note&#13;remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $12,102 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $115,000 which is amortized under the Interest Method over the life of the Note. As of&#13;December 31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On May 20, 2019 the Company determined that&#13;it was in default of the Terms and Conditions of the Note as a result of delinquency by the Company in fulfilling its reporting obligations&#13;under the Securities and Exchange Act of 1934 (&amp;#8220;Exchange Act Default&amp;#8221;). In the event of an Exchange Act Default, the Holder&#13;shall be entitled to use the lowest Bid Price during the delinquency period as a base price for conversion and the Company shall be charged&#13;the default interest rate of 24%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 6, 2017 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of $50,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is December 6, 2020. The Note may be converted&#13;into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to&#13;the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by&#13;the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company (&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $50,000 of the principal&#13;amount of the Note remains outstanding.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $20,000 was recognized by the Company as of &amp;#160;December 31, 2020.&#13;The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As&#13;of December 31, 2020 the unamortized discount on the convertible note outstanding is $136.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On January 24, 2018 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $25,000 for consideration consisting of $25,000 cash.&#13;The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is December 6, 2020. The Note may be converted&#13;into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a) a 75% discount to&#13;the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by&#13;the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company (&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"&gt;In the event , part of the outstanding and unpaid principal amount&#13;of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three&#13;(3) month anniversary of the Maturity Date of the Note&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $25,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $10,000 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $25,000 which is amortized under the Interest Method over the life of the Note. As of December&#13;31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On February 28, 2018 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a two Convertible Notes (&amp;#8220;Notes&amp;#8221;) in the aggregate face amount of $100,000 for consideration consisting&#13;of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Notes is February 28, 2021. The Notes&#13;may be converted into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to the lower of (a)&#13;a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice&#13;is given by the Lender to Regen or (b) $0.025 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of these Notes, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Notes in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the notes, or if the Lender chooses not to convert the remaining amount of the notes into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Notes into Common shares of the Company. The warrants shall have a strike price of $0.025 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Notes on or prior to the close of business on the three (3) month anniversary of the date that the Notes shall have&#13;been prepaid by the Company (&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Notes, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Notes&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $100,000 of the principal&#13;amount of the Notes remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Notes for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $40,000 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Notes amounted in a discount of $100,000 which is amortized under the Interest Method over the life of the Notes. As of&#13;December 31, 2020 the unamortized discount on the convertible notes outstanding is $6,843.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On May 18, 2018 the Company issued a Convertible&#13;Note (&amp;#8220;Note&amp;#8221;)in the principal amount of $114,000 for net consideration of $100,000. The Company recognized an Original Issue&#13;Discount of $14,000 in connection with the Note. The Note bears simple interest of 10%.The Note matures on February 18, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Note may be converted into the Common Shares&#13;of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to equal the lesser of (i) the lowest Trading Price during&#13;the previous twenty-five (25) Trading Day period ending on the latest complete Trading Day prior to the date of the Note and (ii) the&#13;Variable Conversion Price. &amp;#8220;Variable Conversion Price&amp;#8221; shall mean 50% multiplied by the Market Price (representing a discount&#13;rate of 50%). &amp;#8220;Market Price&amp;#8221; means the lowest Trading Price for the Common Stock during the twenty-five (25) Trading Day period&#13;ending on the latest complete Trading Day prior to the Conversion Date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a)&amp;#160;At any time during the period beginning&#13;on the Issue Date and ending on the date which is ninety (90) days following the Issue Date, the Borrower shall have the right, exercisable&#13;on not less than three (3) Trading Days prior written notice to the Holder of the Note to prepay the outstanding Note (principal and accrued&#13;interest), in full by making a payment to the Holder of an amount in cash equal to 135%, multiplied by the sum of: (w) the then outstanding&#13;principal amount of this Note plus (x) accrued and unpaid interest on the unpaid principal amount of this Note plus (y) Default Interest,&#13;if any.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b)&amp;#160;At any time during the period beginning&#13;the day which is ninety one (91) days following the Issue Date and ending on the date which is one hundred eighty (180) days following&#13;the Issue Date, the Borrower shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Holder&#13;of the Note to prepay the outstanding Note (principal and accrued interest), in full by making a payment to the Holder of an amount in&#13;cash equal to 150%, multiplied by the sum of: (w) the then outstanding principal amount of this Note plus (x) accrued and unpaid interest&#13;on the unpaid principal amount of this Note plus (y) Default Interest, if any.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(c)&amp;#160;After the expiration of one hundred&#13;eighty (180) days following the date of the Note, the Borrower shall have no right of prepayment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On July 30, 2019 the Company and the holder&#13;of the Note agreed to the addition of $9,971 to the remaining balance of the Note for consideration to the Company of $9,971.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $65149 of the principal&#13;amount of the Notes remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Notes for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $27,145 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $114,000 which is amortized under the Interest Method over the life of the Note. As of&#13;December 31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On July 11, 2018 the Company issued a Convertible&#13;Note (&amp;#8220;Note&amp;#8221;) in the face amount of $11,500 to an entity controlled by the Company&amp;#8217;s then Chief Financial Officer for&#13;consideration consisting of $11,500 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is May&#13;4, 2021. The Note may be converted into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to&#13;the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date&#13;a conversion notice is given by the Lender to Regen or (b) $0.01 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii) One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"&gt;(b) The granting of a license by the Company or by KCL Therapeutics&#13;, Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company&amp;#8217;s&#13;proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.01 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company (&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $11,500 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Notes for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $4,600 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Notes amounted in a discount of $11,500 which is amortized under the Interest Method over the life of the Notes. As of&#13;December 31, 2020 the unamortized discount on the convertible note outstanding is $1,431.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On September 30, 2018 Regen Biopharma, Inc.&#13;(&amp;#8220;Regen&amp;#8221;) issued a convertible promissory note in the principal amount of $350,000 (&amp;#8220;Note&amp;#8221;) to Zander Therapeutics,&#13;Inc. (&amp;#8220;Zander&amp;#8221;). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount&#13;shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Zander has the right, at any time after the&#13;September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any&#13;other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula:&#13;Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price&#13;is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior&#13;to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion&#13;attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion&#13;shares returned to Regen.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020, 10,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The issuance of the Note amounted in a beneficial&#13;conversion feature of $350,000 which is amortized under the Interest Method over the life of the Note. As of December 31 2020 the unamortized&#13;discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Zander and Regen are under common control.&#13;Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 3, 2018 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $63,000 for consideration consisting of $60,000 cash&#13;and payment on behalf of the Company of $3,000 of expenses incurred in connection with the issuance of the Note. The Note pays simple&#13;interest in the amount of 8% per annum. The maturity of the Note is October 3, 2019. The Note may be converted into the Common Shares&#13;of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to 65% of the lowest Trading Price of the Common Stock of the&#13;Company as reported on the National Quotations Bureau OTC Markets exchange upon which the Company's shares are traded or any exchange&#13;upon which the Common Stock of the Company may be traded in the future , for the twenty prior trading days including the day upon which&#13;a Notice of Conversion is received by the Company or its transfer agent. . In no event shall the Holder be allowed to effect a conversion&#13;if such conversion, along with all other shares of Company Common Stock beneficially owned by the Holder and its affiliates would exceed&#13;9.9% of the outstanding shares of the Common Stock of the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Note may be prepaid with the following&#13;penalties:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 50%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Time Period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 50%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Payment Premium&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#60;=60 days after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;115% of the sum of principal&amp;#160;&amp;#160;plus accrued interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#62;60 days &amp;#60;= 120 days after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;125% of the sum of principal&amp;#160;&amp;#160;plus accrued interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#62;120 days &amp;#60;=180 days&amp;#160;&amp;#160;after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;135% of the sum&amp;#183; of principal plus accrued&amp;#183; interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;This Note may not be prepaid after the 180th&amp;#160;day.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $23,260 of the Note&#13;remains outstanding which includes an additional $6,712 of principal indebtedness resulting from a penalty due to a default of the Terms&#13;and Conditions of the Note . During the year ended September 30, 2019 the Company determined that it was in default of the Terms and Conditions&#13;of the Note . In the event of a Default, the Holder shall be entitled to use the lowest Bid Price during the delinquency period as a base&#13;price for conversion and the Company shall be charged the default interest rate of 24%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $11,928 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $63,000 which is amortized under the Interest Method over the life of the Note. As of&#13;December 31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 10, 2018 the Company issued a Convertible&#13;Note (&amp;#8220;Note&amp;#8221;) in the face amount of $75,000 for consideration consisting of $71,250 cash and payment on behalf of the Company&#13;of 3,750 of expenses incurred in connection with the issuance of the Note. The Note pays simple interest in the amount of 10% per annum.&#13;The maturity of the Note is October 11, &amp;#160;2019. The Note may be converted into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion&#13;Price&amp;#8221;) equivalent to 60% of the lowest Trading Price of the Common Stock of the Company as reported on the National Quotations&#13;Bureau OTC Markets exchange upon which the Company's shares are traded or any exchange upon which the Common Stock of the Company may&#13;be traded in the future , for the twenty prior trading days including the day upon which a Notice of Conversion is received by the Company&#13;or its transfer agent. In no event shall the Holder be allowed to effect a conversion if such conversion, along with all other shares&#13;of Company Common Stock beneficially owned by the Holder and its affiliates would exceed 4.99% ( which may be increased to 9.99% upon&#13;60 days written notice by the Holder) of the outstanding shares of the Common Stock of the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $19,000 of the Note&#13;remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $7,307 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $75,000 which is amortized under the Interest Method over the life of the Note. As of December&#13;31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On May 20, 2019 the Company determined that&#13;it was in default of the Terms and Conditions of the Note as a result of delinquency by the Company in fulfilling its reporting obligations&#13;under the Securities and Exchange Act of 1934 (&amp;#8220;Exchange Act Default&amp;#8221;). In the event of an Exchange Act Default, the Holder&#13;shall be entitled to use the lowest Bid Price during the delinquency period as a base price for conversion and the Company shall be charged&#13;the default interest rate of 24%.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On January 22, 2019 the Company issued a convertible&#13;note in the face amount of $50,000 (&amp;#8220; Note&amp;#8221;). Consideration for the Note consisted of $47,500 cash and payment of fees associated&#13;with the Note of $2,500. The Note shall accrue simple interest in the amount of 10%. Principal and Accrued Interest is due and payable&#13;on January 22, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Note may be converted into the Common Shares&#13;of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to 60% of the lowest Trading Price of the Common Stock of the&#13;Company as reported on the National Quotations Bureau OTC Markets exchange upon which the Company's shares are traded or any exchange&#13;upon which the Common Stock of the Company may be traded in the future , for the twenty prior trading days including the day upon which&#13;a Notice of Conversion is received by the Company or its transfer agent. In no event shall the Holder be allowed to effect a conversion&#13;if such conversion, along with all other shares of Company Common Stock beneficially owned by the Holder and its affiliates would exceed&#13;4.99% ( which may be increased to 9.99% upon 61 days written notice by the Holder) of the outstanding shares of the Common Stock of the&#13;Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Front End Note may be prepaid with the&#13;following penalties:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 50%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Time Period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 50%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Payment Premium&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#60;=60 days after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;125% of the sum of principal&amp;#160;&amp;#160;plus accrued interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#62;60 days &amp;#60;= 120 days after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;135% of the sum of principal&amp;#160;&amp;#160;plus accrued interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#62;120 days &amp;#60;=180 days&amp;#160;&amp;#160;after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;140% of the sum&amp;#183; of principal plus accrued&amp;#183; interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"&gt;This Note may not be prepaid after the 180th&amp;#160;day.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $19,607 of the Note&#13;remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;br /&gt;&#13;The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and&#13;Hedging&amp;#8221; and determined that the embedded conversion feature should be classified as a liability due to their being no explicit&#13;limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion&#13;features are bifurcated and separately accounted for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The&#13;embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement&#13;period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the&#13;change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $8,169 was recognized by the Company as of December 31, 2020 The issuance&#13;of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December 31,&#13;2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On February 15, 2019 the Company issued a Convertible&#13;Note (&amp;#8220;Note&amp;#8221;) in the face amount of $50,000 for consideration consisting of $47,500 cash and payment on behalf of the Company&#13;of $2,500 of expenses incurred in connection with the issuance of the Note. The Note may be converted into the Common Shares of Regen&#13;at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to 60% of the lowest Trading Price of the Common Stock of the Company&#13;as reported on the National Quotations Bureau OTC Markets exchange upon which the Company's shares are traded or any exchange upon which&#13;the Common Stock of the Company may be traded in the future , for the twenty prior trading days including the day upon which a Notice&#13;of Conversion is received by the Company or its transfer agent. In no event shall the Holder be allowed to effect a conversion if such&#13;conversion, along with all other shares of Company Common Stock beneficially owned by the Holder and its affiliates would exceed 4.99%&#13;( which may be increased to 9.99% upon 61 days written notice by the Holder) of the outstanding shares of the Common Stock of the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Note may be prepaid with the following&#13;penalties:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 47%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Time Period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 43%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Payment Premium&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#60;=90 days after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;135% of the sum of principal&amp;#160;&amp;#160;plus accrued interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;This Note may not be prepaid after the 90th&amp;#160;day.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $19,018 of the Note&#13;remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $7,924 was recognized by the Company as of December 31, 2020. The&#13;issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of December&#13;31, 2020 the unamortized discount on the convertible note outstanding is $0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On May 20, 2019 the Company determined that&#13;it was in default of the Terms and Conditions of the Note as a result of delinquency by the Company in fulfilling its reporting obligations&#13;under the Securities and Exchange Act of 1934 (&amp;#8220;Exchange Act Default&amp;#8221;). In the event of an Exchange Act Default, the Holder&#13;shall be entitled to use the lowest Bid Price during the delinquency period as a base price for conversion and the Company shall be charged&#13;the default interest rate of 24%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On July 19, 2019 the Company issued a convertible&#13;promissory note in the face amount of $100,000 (&amp;#8220;Note&amp;#8221;) for consideration consisting of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;$95,000 cash&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;the payment of $5,000 of legal fees&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Note pays simple interest in the amount&#13;of 10% per annum. The maturity of the Note is July 19, 2020. The Note may be converted into the common stock of Regen at a price per share&#13;( &amp;#8220;Conversion Price&amp;#8221;) equivalent to 60% of the lowest Trading price of the common stock of the Company as reported on the&#13;National Quotations Bureau OTC Markets exchange upon which the Company's shares are traded or any exchange upon which the Common Stock&#13;of the Company may be traded in the future , for the twenty prior trading days including the day upon which a Notice of Conversion is&#13;received by the Company or its transfer agent. . In no event shall the Holder be allowed to effect a conversion if such conversion, along&#13;with all other shares of Company common stock beneficially owned by the Holder and its affiliates would exceed 9.9% of the outstanding&#13;shares of the Common Stock of the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The proceeds from the issuance of the Note&#13;are to be allocated as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;$30,592 will be utilized to retire the outstanding&#13;balance of a $75,000 note issued by the Company on August 15, 2018 to One44 capital, LLC and $22,877 will be allocated to the Company&amp;#8217;s&#13;accountants and auditors to bring the Company current with regards to the Company&amp;#8217;s quarterly reporting requirements under the Securities&#13;and Exchange Act of 1934.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Note may be prepaid with the following&#13;penalties:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 50%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Time Period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 50%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Payment Premium&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#60;=60 days after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;125% of the sum of principal&amp;#160;&amp;#160;plus accrued interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#62;60 days &amp;#60;= 120 days after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;135% of the sum of principal&amp;#160;&amp;#160;plus accrued interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#62;120 days &amp;#60;=180 days&amp;#160;&amp;#160;after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;140% of the sum&amp;#183; of principal plus accrued&amp;#183; interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;This Note may not be prepaid after the 180th&amp;#160;day.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $100,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $55,555 was recognized by the Company as of December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The issuance of the Note amounted in a discount&#13;of $100,000 which is amortized under the Interest Method over the life of the Note. As of December 31, 2020 the unamortized discount on&#13;the convertible note outstanding is $ 0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On July 19, 2019 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $20,331 for consideration consisting of $18,831 cash&#13;and payment on behalf of the Company of $1,500 of expenses incurred in connection with the issuance of the Note. The Note pays simple&#13;interest in the amount of 8% per annum. The maturity of the Note is July 19, 2019. The Note may be converted into shares of the common&#13;stock of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to 65% of the lowest Trading price of the common stock&#13;of the Company as reported on the National Quotations Bureau OTC Markets exchange upon which the Company's shares are traded or any exchange&#13;upon which the Common Stock of the Company may be traded in the future , for the twenty prior trading days including the day upon which&#13;a Notice of Conversion is received by the Company or its transfer agent. . In no event shall the Holder be allowed to effect a conversion&#13;if such conversion, along with all other shares of Company common stock beneficially owned by the Holder and its affiliates would exceed&#13;9.9% of the outstanding shares of the Common Stock of the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Note may be prepaid with the following&#13;penalties:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 50%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Time Period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 50%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Payment Premium&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#60;=60 days after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;115% of the sum of principal&amp;#160;&amp;#160;plus accrued interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#62;60 days &amp;#60;= 120 days after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;125% of the sum of principal&amp;#160;&amp;#160;plus accrued interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#62;120 days &amp;#60;=180 days&amp;#160;&amp;#160;after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;135% of the sum&amp;#183; of principal plus accrued&amp;#183; interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;This Note may not be prepaid after the 180th&amp;#160;day.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $20,331 of principal&#13;indebtedness owed on the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $7,819 was recognized by the Company as of December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The issuance of the Note amounted in a discount&#13;of $20,331 which is amortized under the Interest Method over the life of the Note. As of December 31,2020 2020 the unamortized discount&#13;on the convertible note outstanding is $ 0.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On July 19, 2019 (&amp;#8220;Issue date&amp;#8221;)&#13;the Company issued a Convertible Note (&amp;#8220;Note&amp;#8221;) in the face amount of $14,819 for consideration consisting of $13,319 cash&#13;and payment on behalf of the Company of $1,500 of expenses incurred in connection with the issuance of the Note. The Note pays simple&#13;interest in the amount of 10% per annum. The maturity of the Note is July 19, 2019. The Note may be converted into shares of the common&#13;stock of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to 60% of the lowest Trading price of the common stock&#13;of the Company as reported on the National Quotations Bureau OTC Markets exchange upon which the Company's shares are traded or any exchange&#13;upon which the Common Stock of the Company may be traded in the future , for the twenty prior trading days including the day upon which&#13;a Notice of Conversion is received by the Company or its transfer agent. . In no event shall the Holder be allowed to effect a conversion&#13;if such conversion, along with all other shares of Company common stock beneficially owned by the Holder and its affiliates would exceed&#13;9.9% of the outstanding shares of the Common Stock of the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Note may be prepaid with the following&#13;penalties:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 50%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Time Period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; width: 50%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Payment Premium&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#60;=60 days after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;125% of the sum of principal&amp;#160;&amp;#160;plus accrued interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#62;60 days &amp;#60;= 120 days after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;135% of the sum of principal&amp;#160;&amp;#160;plus accrued interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#62;120 days &amp;#60;=180 days&amp;#160;&amp;#160;after note issuance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;140% of the sum&amp;#183; of principal plus accrued&amp;#183; interest&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;This Note may not be prepaid after the 180th&amp;#160;day.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $14,819 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company analyzed the conversion feature&#13;of the Note for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives and Hedging&amp;#8221; and determined that the embedded&#13;conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon&#13;settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted&#13;for as an embedded derivative contained in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet&#13;at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income&#13;statement and the associated carrying amount on the balance sheet is adjusted by the change.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company values the embedded derivative&#13;using the Black-Scholes pricing model and a derivative liability of $6,174 was recognized by the Company as of December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The issuance of the Note amounted in a discount&#13;of $14,819 which is amortized under the Interest Method over the life of the Note. As of December 31, 2020 the unamortized discount on&#13;the convertible note outstanding is $0.&lt;/p&gt;</RGBP:ConvertibleNotesPayableTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;NOTE 6. RELATED PARTY TRANSACTIONS&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On June 23, 2015 the Company entered into an&#13;agreement (&amp;#8220;Agreement&amp;#8221;) with Zander Therapeutics, Inc. ( &amp;#8220;Zander&amp;#8221;) whereby The Company granted to Zander an exclusive&#13;worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (&amp;#8221;&#13;License IP&amp;#8221;) for non-human veterinary therapeutic use for a term of fifteen years. Zander is under common control with the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Pursuant to the Agreement, Zander shall pay&#13;to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which&#13;must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July&#13;15th, 2016 and each subsequent anniversary of the effective date of the Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The abovementioned payments may be made, at&#13;Zander&amp;#8217;s discretion, in cash or newly issued common stock of Zander.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Pursuant to the Agreement, Zander shall pay&#13;to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products,&#13;as such term is defined in the Agreement, in a Quarter.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Pursuant to the Agreement, Zander will pay&#13;The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration)&#13;received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The&#13;Company receives payment pursuant to the terms and conditions of the Agreement).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Zander is obligated pay to The Company minimum&#13;annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing&#13;on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during&#13;the preceding 12-month period do not exceed ten thousand US dollars ($10,000).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Agreement may be terminated by The Company:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;If Zander has not sold any Licensed Product&#13;by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after&#13;Zander&amp;#8217;s first commercial sale of a Licensed Product.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Agreement may be terminated by Zander with&#13;regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United&#13;States patent and Trademark Office to The Company with regard to that License IP.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Agreement may be terminated by Zander with&#13;regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with&#13;regard to that License IP is terminated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Agreement may be terminated by either party&#13;in the event of a material breach by the other party.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 17, 2018 Regen Biopharma, Inc.(&amp;#8220;Licensor&amp;#8221;)&#13;, KCL Therapeutics, Inc. (&amp;#8220;Assignee&amp;#8221;) and Zander Therapeutics, Inc. (&amp;#8220;Licensee&amp;#8221;) entered into a LICENSE ASSIGNMENT&#13;AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(&amp;#8220;Assigned&#13;Properties&amp;#8221;) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights,&#13;duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties&#13;and obligations thereunder and be bound to the terms of the Agreement with respect thereto.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 16, 2019 Zander Therapeutics, Inc.&#13;(&amp;#8220;Zander&amp;#8221;), KCL Therapeutics, Inc. (&amp;#8220;KCL&amp;#8221;) and Regen Biopharma, Inc. (&amp;#8220;Regen&amp;#8221;) entered into an agreement&#13;(&amp;#8220;Agreement&amp;#8221;) whereby:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;1) Zander shall return for cancellation 194,285,714&#13;shares of the Series A Preferred stock of Regen (&amp;#8220;Conversion Shares&amp;#8221;) acquired by Zander through conversion of $340,000 of&#13;principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount&#13;due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;2) A $35,000 one time charge due to Zander&#13;by Regen (&amp;#8220;One Time Charge&amp;#8221;) shall be applied pursuant to the Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;3) $75,900 of principal indebtedness due to&#13;Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;No actions were taken by any of the parties&#13;to enforce the terms of the Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On April 15, 2021 the Agreement was amended&#13;as follows so that the material terms and conditions shall be:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;a)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Zander&#13;shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not&#13;reflect such return&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;b)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;As&#13;of December 16, 2019 all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued&#13;by Regen to Zander shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between&#13;Zander and Regen on June 23, 2015 (&amp;#8220;License Agreement&amp;#8221;) whereby Regen granted to Zander an exclusive worldwide right and license&#13;for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use&#13;for a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on December&#13;17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License Agreement and KCL&#13;agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with respect thereto.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Zander and Regen are under common control.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On July 11, 2018 the Company issued a Convertible&#13;Note (&amp;#8220;Note&amp;#8221;) in the face amount of $11,500 to an entity controlled by the Company&amp;#8217;s then Chief Financial Officer for&#13;consideration consisting of $11,500 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is May&#13;4, 2021. The Note may be converted into the Common Shares of Regen at a price per share ( &amp;#8220;Conversion Price&amp;#8221;) equivalent to&#13;the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date&#13;a conversion notice is given by the Lender to Regen or (b) $0.01 per common share as of the date which is the earlier of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(i)&amp;#160;One day subsequent to the execution&#13;of an agreement to a transaction whose completion would result in a &amp;#8220;Change of Control&amp;#8221; of the Company or KCL Therapeutics.&#13;For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale&#13;of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity&#13;in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute&#13;a majority of the Board of Directors of the surviving entity following the closing of such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(ii)&amp;#160;One day subsequent to the commencement,&#13;in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company&amp;#8217;s outstanding&#13;equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities&#13;(&amp;#8220;Tender Offer&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(iv) One day subsequent to a &amp;#8220;Transaction&#13;Event&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Transaction Event&amp;#8221; shall mean either&#13;of:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(a) The sale by the Company or by KCL Therapeutics&#13;, Inc. of the Company&amp;#8217;s proprietary NR2F6 intellectual property to an unaffiliated third party&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(b) The granting of a license by the Company&#13;or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize&#13;the Company&amp;#8217;s proprietary NR2F6 intellectual property&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;(v) That date which is twenty four (24) months&#13;subsequent to the date of execution of this Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Company shall have the right, exercisable&#13;on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including&#13;outstanding principal and accrued interest.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that that the Company exercises&#13;its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company,&#13;the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount&#13;of the Note into Common shares of the Company. The warrants shall have a strike price of $0.01 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The warrants shall be exercisable:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event that the Company exercises its&#13;right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have&#13;been prepaid by the Company (&amp;#8220;Prepayment Date&amp;#8221;)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;In the event , part of the outstanding and&#13;unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close&#13;of business on the three (3) month anniversary of the Maturity Date of the Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020 $11,500 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On September 30, 2018 Regen Biopharma, Inc.&#13;(&amp;#8220;Regen&amp;#8221;) issued a convertible promissory note in the principal amount of $350,000 (&amp;#8220;Note&amp;#8221;) to Zander Therapeutics,&#13;Inc. (&amp;#8220;Zander&amp;#8221;). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount&#13;shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Zander has the right, at any time after the&#13;September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any&#13;other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number&#13;of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the&#13;greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling&#13;all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable&#13;to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned&#13;to Regen.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;As of December 31, 2020, $10,000 of the principal&#13;amount of the Note remains outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;As of December 31, 2020 the&#13;Company is indebted to David R. Koos the Compoany&amp;#8217;s sole officer and director in the amount of $227. $227 lent to the Company by&#13;Koos is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;As of December 31, 2020 the&#13;Company is indebted to BST Partners, an entity controlled by the Company&amp;#8217;s Chairman and CEO, in the amount of $61,900.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:AccountsAndNontradeReceivableTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;NOTE 7. ACCOUNTS RECEIVABLE,&#13;RELATED PARTY&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Accounts Receivable due from&#13;Related Party as of December 31, 2020 consists solely of amounts earned by the Company not yet paid resulting from the Company&amp;#8217;s&#13;license agreement with KCL Therapeutics&amp;#160;( See Note 6).&lt;/p&gt;</us-gaap:AccountsAndNontradeReceivableTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;NOTE 8. COMMITMENTS AND CONTINGENCIES&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On December 13, 2019 a complaint&#13;was filed in the Superior Court of California, County of San Diego&amp;#160; against&amp;#160; Regen Biopharma, Inc. (&amp;#8220;Company&amp;#8221;) ,&amp;#160;&#13;the Company&amp;#8217;s Chairman, Zander Therapeutics Inc (&amp;#8220;Zander&amp;#8221;), and&amp;#160;Does 1-50 by ChemDiv, Inc. (&amp;#8220;Plaintiff&amp;#8221;)&#13;alleging&amp;#160; Breach of Contract, Unfair Business Practices under the California Business and Professions Code, and&amp;#160; Bad Faith Denial&#13;of a Contract ( alleged solely against the Company&amp;#160; and DOE defendants) stemming from contract research work performed by the Plaintiff&#13;for the Company and contract research performed by the Plaintiff for Zander. The Plaintiff is also seeking a declaration from the court&#13;that the Plaintiff retains full and complete ownership, title, use, and all rights without any limits to the work, tangible property,&#13;intellectual property, and any other product or by-product of the work performed by Plaintiff for the Company and Zander. The action arises&#13;from approximately $1.2 million dollars of unpaid invoices (&amp;#8220;Unpaid Invoices&amp;#8221;) due and payable to the Plaintiff. The Company&#13;believes that no portion of the Unpaid Invoices are due and payable by the Company. The outcome of this legal proceeding may adversely&#13;affect the Company&amp;#8217;s financial condition and operations and may also result in loss of control by the Company of certain intellectual&#13;property controlled by the Company.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;NOTE 9. STOCKHOLDERS&amp;#8217;&#13;EQUITY&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The stockholders&amp;#8217; equity&#13;section of the Company contains the following classes of capital stock as of December 31, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Common stock, $ 0.0001 par value;&#13;4, 800,000,000 shares authorized: 2,260,025,066 &amp;#160;shares issued and outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;With respect to each matter&#13;submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which&#13;is equivalent to the number of shares of Common Stock owned by such holder times one (1).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On any voluntary or involuntary&#13;liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available&#13;for distribution to the Company&amp;#8217;s stockholders, a ratable share in the assets of the Corporation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Preferred Stock, $0.0001 par&#13;value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 50,000 shares issued and outstanding&#13;as of December 31, 2020, 300,000,000 is designated Series A Preferred Stock of which 414147858 shares are outstanding as of December 31,&#13;2020 and 300,000,000 is designated Series M Preferred Stock of which 44,000,000 shares are outstanding as of December 31, 2020.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The abovementioned shares authorized&#13;pursuant to the Company&amp;#8217;s certificate of incorporation may be issued from time to time without prior approval of the shareholders.&#13;The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of&#13;shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such&#13;designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series&#13;of the Stock that may be desired.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Series AA Preferred Stock&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On September 15, 2014 the Company&#13;filed a CERTIFICATE OF DESIGNATION (&amp;#8220;Certificate of Designations&amp;#8221;) with the Nevada Secretary of State setting forth the preferences&#13;rights and limitations of a newly authorized series of preferred stock designated and known as &amp;#8220;Series AA Preferred Stock&amp;#8221;&#13;(hereinafter referred to as &amp;#8220;Series AA Preferred Stock&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Board of Directors of the&#13;Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a&#13;vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which&#13;is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise&#13;required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote&#13;as a single class on all matters submitted to the stockholders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Series A Preferred Stock&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On January 15, 2015 the Company&#13;filed a CERTIFICATE OF DESIGNATION (&amp;#8220;Certificate of Designations&amp;#8221;) with the Nevada Secretary of State setting forth the preferences&#13;rights and limitations of a newly authorized series of preferred stock designated and known as &amp;#8220;Series A Preferred Stock&amp;#8221;&#13;(hereinafter referred to as &amp;#8220;Series A Preferred Stock&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Board of Directors of the&#13;Company have authorized 300,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to&#13;a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which&#13;is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law&#13;holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class&#13;on all matters submitted to the stockholders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Holders of the Series A Preferred&#13;Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the &amp;#8220;Board&amp;#8221;) out of&#13;funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid&#13;or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date&#13;established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the&#13;&amp;#8220;Additional Dividends&amp;#8221;) an amount (whether in the form of cash, securities or other property) equal to the amount (and in&#13;the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one&#13;share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Upon any liquidation, dissolution,&#13;or winding up of the Company, whether voluntary or involuntary (collectively, a &amp;#8220;Liquidation&amp;#8221;), before any distribution or&#13;payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred&#13;Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal&#13;to $0.01 per share of Series A Preferred (the &amp;#8220;Liquidation Amount&amp;#8221;) plus all declared and unpaid dividends thereon, for each&#13;share of Series A Preferred held by them.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;If, upon any Liquidation, the&#13;assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full&#13;to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A&#13;Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may&#13;be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On January 10, 2017 Regen Biopharma,&#13;Inc. (&amp;#8220;Regen&amp;#8221;) filed a CERTIFICATE OF DESIGNATION (&amp;#34;Certificate of Designations&amp;#34;) with the Nevada Secretary of&#13;State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as &amp;#34;Series&#13;M Preferred Stock&amp;#34; (hereinafter referred to as &amp;#34;Series M Preferred Stock&amp;#34;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Board of Directors of Regen&#13;have authorized 300,000,000 shares of the Series M Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote&#13;of stockholders of Regen, each holder of Series M Preferred Stock shall be entitled to cast that number of votes which is equivalent to&#13;the number of shares of Series M Preferred Stock owned by such holder times one. Except as otherwise required by law holders of Common&#13;Stock, other series of Preferred issued by Regen, and Series M Preferred Stock shall vote as a single class on all matters submitted to&#13;the stockholders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The holders of Series M Preferred&#13;Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion,&#13;from funds legally available therefore&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On any voluntary or involuntary&#13;liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available&#13;for distribution to Regen&amp;#8217;s stockholders, a ratable share in the assets of Regen.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <RGBP:InvestmentSecuritiesTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;NOTE 10. INVESTMENT SECURITIES&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On June 11, 2018 Regen Biopharma,&#13;Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On November 29, 2018 the Company&#13;accepted 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest&#13;owed to the Company collectively amounting to $13,124.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On December 31, 2020 the Company&#13;revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics,&#13;Inc. based on the following inputs:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 71%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Fair Value of Intellectual Property&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Prepaid Expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;74,298&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Due from Employee&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,071&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Note Receivable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;64,400&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Accrued Interest Receivable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;20,274&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Investment Securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;593,357&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Convertible Note Receivable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Accounts Payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,269,041&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Notes Payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Accrued Expenses Related Parties&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;89,529&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Accrued Expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;203,037&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Enterprise Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,826,507&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Less: Total Debt&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(2,061,607&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Portion of Enterprise Value Attributable to Shareholders&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;764,900&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Fair Value&amp;#160;&amp;#160;Per Share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.0167&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The abovementioned constitute the Company&amp;#8217;s&#13;sole investment securities as of December 31, 2020&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; background-color: white"&gt;&lt;b&gt;As of December 31,&#13;2020:&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; background-color: white"&gt;&lt;b&gt;470,588 Common Shares&#13;of Zander Therapeutics, Inc.&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Basis&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Fair Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Total Unrealized &lt;br /&gt;&#13;Gains&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Net Unrealized Gain or (Loss) realized during the Quarter ended December 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,741&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,858&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,118&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"&gt;&lt;b&gt;725,000 Series M Preferred of Zander Therapeutics, Inc.&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Basis&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Fair Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Total Unrealized Loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Net Unrealized Gain or (Loss) realized during the Quarter &amp;#160;ended December 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;13,124&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,109&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,104&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;</RGBP:InvestmentSecuritiesTextBlock>
    <RGBP:StockTransactionsTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;NOTE 11. STOCK TRANSACTIONS&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Issuance of Common Shares:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On October 28, 2020 the Company issued 80,065,846&#13;common shares in satisfaction of $3,752 of convertible indebtedness and $1,452 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On November 6, 2020 the Company issued 83,934,153&#13;common shares in satisfaction of $3,900 of convertible indebtedness and $1,555 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 11, 2020 the Company issued 87,020,000&#13;common shares in satisfaction of $7,300 of convertible indebtedness and $3,142 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 16, 2020 the Company issued 6,437,153&#13;common shares in satisfaction of $429 of convertible indebtedness and $236 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 16, 2020 the Company issued 88,158,923&#13;common shares in satisfaction of $4,030 of convertible indebtedness and $1,700 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 17, 2020 the Company issued 83,216,917&#13;common shares in satisfaction of $8,200 of convertible indebtedness and $1,786 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 23, 2020 the Company issued 108,444,444&#13;common shares in satisfaction of $16,000 of convertible indebtedness and $3,250 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 31, 2020 the Company issued 117,837,384&#13;common shares in satisfaction of $5,330 of convertible indebtedness and $2,329 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Issuance of Series A Preferred&#13;Shares:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On December 17, 2020 the Company issued 32,379,169&#13;shares of Series A Preferred stock in satisfaction of $13,000 of convertible indebtedness and $8,046 of accrued interest on convertible&#13;indebtedness.&lt;/p&gt;</RGBP:StockTransactionsTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;NOTE 12. SUBSEQUENT EVENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Issuance of Shares&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On January 28, 2021 the Company issued 85,900,000&#13;common shares in satisfaction of $5,154 of convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On February 23, 2021 the Company issued 88,000,000&#13;common shares in satisfaction of $4,400 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On February 24, 2021 the Company issued 82,759,286&#13;common shares in satisfaction of $30,000 of convertible indebtedness and $4,758 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On March 2, 2021 the Company issued 119,269,538&#13;common shares in satisfaction of $5,260 of convertible indebtedness and $2,492 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On March 18, 2021 the Company issued 70,000,000&#13;common shares in satisfaction of $3,415 of convertible indebtedness and $84 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On March 31, 2021 the Company issued 40,000,000&#13;common shares in satisfaction of $1926 of convertible indebtedness and $74 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On April 12, 2021 the Company issued 85,000,000&#13;common shares in satisfaction of $3111 of convertible indebtedness and $49 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On April 13, 2021 the Company issued 83,636,833&#13;common shares in satisfaction of $3,511 of convertible indebtedness and $1508 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On April 13, 2021 the Company&#13;issued 10,000 Series NC Preferred shares to its Chief Executive Officer as consideration for services.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On April 13, 2021 the Company issued 32,968,042&#13;common shares in satisfaction of $19,000 of convertible indebtedness and $4736 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On April 15, 2021 the Company issued 146,452,000&#13;common shares in satisfaction of $1,416 of convertible indebtedness and $680 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On April 15, 2021 the Company issued 49482000&#13;common shares in satisfaction of $2288 of convertible indebtedness and $680 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On April 16, 2021 the Company issued 70,755,885&#13;common shares in satisfaction of $47,000 of convertible indebtedness and $8,189 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On April 16, 2021 the Company issued 90,311,411&#13;common shares in satisfaction of $4,238 of convertible indebtedness and $17 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On April 21, 2021 the Company issued 163,814,000&#13;common shares in satisfaction of $7564 of convertible indebtedness and $2,264 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On April 28, 2021 the Company issued 28,784,167&#13;common shares in satisfaction of $22,000 of convertible indebtedness and $3,905 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On May 3, 2021 the Company issued 33,012,555&#13;common shares in satisfaction of $1,416 of convertible indebtedness and $729 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On May 5, 2021 the Company issued 27,753,016&#13;common shares in satisfaction of $1,187 of convertible indebtedness and $616 of accrued interest on convertible indebtedness.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Certificate of Designations&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;On March 26, 2021 Regen Biopharma, Inc. ( &amp;#8220;Regen&amp;#8221;)&#13;filed a CERTIFICATE OF DESIGNATION (&amp;#34;Certificate of Designations&amp;#34;) with the Nevada Secretary of State setting forth the preferences&#13;rights and limitations of a newly authorized series of preferred stock designated and known as Nonconvertible Series NC Preferred Stock&#13;(hereinafter referred to as &amp;#34;Series NC Preferred Stock&amp;#34;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Board of Directors of Regen have authorized&#13;20,000 shares of the Series NC Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of&#13;Regen, each holder of Series NC Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares&#13;of Series NC Preferred Stock owned by such holder times 500,000. Except as otherwise required by law holders of Common Stock, other series&#13;of Preferred issued by Regen, and Series NC Preferred Stock shall vote as a single class on all matters submitted to the stockholders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The holders of Series NC Preferred Stock shall&#13;be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from&#13;funds legally available therefore&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On any voluntary or involuntary liquidation, dissolution or winding up&#13;of Regen, the holders of the Series NC Preferred Stock shall receive, out of assets legally available for distribution to Regen&amp;#8217;s&#13;stockholders, a ratable share in the assets of Regen.&amp;#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; background-color: white"&gt;&lt;b&gt;As of December 31,&#13;2020:&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; background-color: white"&gt;&lt;b&gt;470,588 Common Shares&#13;of Zander Therapeutics, Inc.&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Basis&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Fair Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Total Unrealized &lt;br /&gt;&#13;Gains&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Net Unrealized Gain or (Loss) realized during the Quarter ended December 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,741&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,858&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,118&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"&gt;&lt;b&gt;725,000 Series M Preferred of Zander Therapeutics, Inc.&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Basis&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Fair Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Total Unrealized Loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Net Unrealized Gain or (Loss) realized during the Quarter &amp;#160;ended December 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;13,124&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,109&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,104&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;</us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;On December 31, 2020 the Company&#13;revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics,&#13;Inc. based on the following inputs:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 71%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Fair Value of Intellectual Property&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Prepaid Expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;74,298&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Due from Employee&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,071&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Note Receivable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;64,400&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Accrued Interest Receivable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;20,274&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Investment Securities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;593,357&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Convertible Note Receivable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Accounts Payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,269,041&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Notes Payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Accrued Expenses Related Parties&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;89,529&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Accrued Expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;203,037&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Enterprise Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,826,507&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Less: Total Debt&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(2,061,607&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Portion of Enterprise Value Attributable to Shareholders&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;764,900&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Fair Value&amp;#160;&amp;#160;Per Share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.0167&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The abovementioned constitute the Company&amp;#8217;s&#13;sole investment securities as of December 31, 2020&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeByComponentTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2020-10-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;As of December 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 71%"&gt;&lt;font style="font-size: 10pt"&gt;David Koos&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;227&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;BST Partners&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;61,900&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Total:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Black Scholes pricing model used to determine&#13;the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of December 31, 2020&#13;utilized the following inputs:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Risk Free Interest Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected Term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;.34&amp;#8211; -1.87 Yrs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;743%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected Dividends&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;A. BASIS OF ACCOUNTING&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The financial statements have&#13;been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues&#13;are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;B. PRINCIPLES OF CONSOLIDATION&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The consolidated financial statements include&#13;the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions&#13;have been eliminated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;br /&gt;&#13;The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 &amp;#8220;Derivatives&#13;and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained&#13;in the Company&amp;#8217;s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change&#13;in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying&#13;amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model.&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;The Black Scholes pricing model used to determine&#13;the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of December 31, 2020&#13;utilized the following inputs:&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Risk Free Interest Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected Term&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;.34&amp;#8211; -1.87 Yrs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;743%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected Dividends&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;  &lt;/table&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;H. INCOME TAXES&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company accounts for income&#13;taxes using the liability method prescribed by ASC 740, &amp;#8220;Income Taxes.&amp;#8221; Under this method, deferred tax assets and liabilities&#13;are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates&#13;that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset&#13;deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred&#13;tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that&#13;includes the enactment date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company applied the provisions&#13;of ASC 740-10-50, &amp;#8220;Accounting For Uncertainty In Income Taxes&amp;#8221;, which provides clarification related to the process associated&#13;with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute&#13;of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result&#13;in an adjustment to the Company&amp;#8217;s liability for income taxes. Any such adjustment could be material to the Company&amp;#8217;s results&#13;of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of December&#13;31, 2020 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company generated a deferred&#13;tax credit through net operating loss carry forward. &amp;#160;However, a valuation allowance of 100% has been established.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Interest and penalties on tax&#13;deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;I. &amp;#160;BASIC EARNINGS (LOSS)&#13;PER SHARE&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Financial Accounting Standards&#13;Board (FASB) issued Accounting Standards Codification (ASC) 260, &amp;#8220;Earnings Per Share&amp;#8221;, which specifies the computation, presentation&#13;and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation&#13;of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective&#13;from inception.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Basic net loss per share amounts&#13;is computed by dividing the net income by the weighted average number of common shares outstanding.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;J. ADVERTISING&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Costs associated with advertising&#13;are charged to expense as incurred. Advertising expenses were $0 for the quarters ended December 31 2020 and December 31, 2019.&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;K. NOTES RECEIVABLE&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Notes receivable are stated&#13;at cost, less impairment, if any.&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;L. REVENUE RECOGNITION&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Sales of products and related&#13;costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price&#13;is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing&#13;and shipment of products.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;The Company determines the amount&#13;and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty&#13;revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties&#13;are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage&#13;to the Company&amp;#8217;s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee&amp;#8217;s&#13;sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon&#13;satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <RGBP:InterestReceivablePolicyTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;M. INTEREST RECEIVABLE&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"&gt;Interest receivable is stated&#13;at cost, less impairment, if any.&lt;/p&gt;</RGBP:InterestReceivablePolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2020-10-01to2020-12-31" unitRef="Pure" decimals="INF">7.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
</xbrli:xbrl>


